E-cigs vs. T-cigs
Electronic cigarettes may be less harmful in the UK than cigarettes but may still be dangerous. Under which circumstances should a person use ecigs? Will they fill your body with plastic?
Electronic cigarettes can contain propylene glycol or vegetable glycerine with nicotine (and in at least two cases polyethylene glycol 400) to form a solution that when heated by an atomizer, produces a visible vapour that provides nicotine to the bloodstream via the lungs when inhaled.
Electronic cigarettes have not been studied enough by scientists in laboratories to form conclusive evidence that their use is either beneficial or harmful to humans. However, some are concerned that unknown side-effects could occur with continuous, consistent use of electronic cigarettes, including cancer.
Behaviour surrounding their use is worrisome because e-cigs are being used habitually by a percentage of non-smokers who otherwise would not use nicotine, they may seem attractive to children, they are not closely regulated, and their use makes it very easy to overdose on nicotine even for experienced smokers.
UK Electronic Cigarettes and E-Liquid
E-cigs vs. T-cigs
Electronic cigarettes may be less harmful than cigarettes but may still be dangerous. Under which circumstances should a person use electronic cigarettes? Will they fill your body with plastic?
Electronic cigarettes can contain propylene glycol or vegetable glycerine with nicotine (and in at least two cases polyethylene glycol 400) to form a solution that when heated by an atomizer, produces a visible vapour that provides nicotine to the bloodstream via the lungs when inhaled.
Electronic cigarettes have not been studied enough by scientists in laboratories to form conclusive evidence that their use is either beneficial or harmful to humans. However, some are concerned that unknown side-effects could occur with continuous, consistent use of electronic cigarettes, including cancer.
Behaviour surrounding their use is worrisome because e-cigs are being used habitually by a percentage of non-smokers who otherwise would not use nicotine, they may seem attractive to children, they are not closely regulated, and their use makes it very easy to overdose on nicotine even for experienced smokers.
Additionally, they're being marketed to children.
Do E-cigs Impact Society?
Are electronic cigarettes safe to use in public?
Many countries, states, cities, companies, bars and restaurants, and other organizations are banning the use of electronic cigarettes. There are a variety of reasons for their ban.
In 'Drugs And Society' by Glen R. Hanson, Peter J. Venturelli, Annette E. Fleckenstein, the implications the use of drugs has on society is explored in detail. The findings are quite fascinating.
De-icing your lungs?
Many articles about e-cigarettes will focus on the legality of their use and sale, their addictiveness, and the demographics who uses them. What few articles mention though, is what the ingredients in electronic cigarettes are and why you may not want them in your body.
Propylene glycol is basically plastic. Actually it's an additive for manufacturing plastic. The single largest use of PG is for the production of unsaturated polyester resins. It is also used as a humectant (an additive that keeps something moist), and as a preservative for food and tobacco. Mmm, yummy.
Propylene glycol has similar thermal properties to ethylene glycol in that it can lower the freezing point of water when added to it. As a result, propylene glycol is often used as aircraft de-icing fluid, according to Steve Ritter's article What's That Stuff?" on the C&EN website.
Another fun fact: disclosure of which chemicals are in any given electronic cigarette are often not made available by manufacturers or retailers. The most recent information regarding the health effects on humans of acute exposure to propylene glycol by inhalation is from 2002. Please find this information made available by the EPA at the bottom of this article.
Formaldehyde in Cigarettes; Nicotine could Kill a Child
You are probably not a doctor (although, you might be), and you probably rely on the advice of experts for medical information and health recommendations. Using your best judgement, do you think that electronic cigarettes are safe to use? Would you recommend using an electronic cigarette to your friends and family? How about your kids?
Take a look at this video from reports in France. It says that e-cigarettes contain level of formaldehyde near that of tobacco cigarettes. What? I do not know if that information is true, but if it is, it's not good!
The reports urge people to understand that electronic cigarettes are not healthy. Furthermore, the reports say that some models of e-cigarette do not have protective safety caps even though they have enough nicotine to kill a child. That is a liability. Yikes!
- The molecular formula for propylene glycol is C3H8O2
- It is a clear and colorless liquid and is non-corrosive
- It is unknown whether or not is adversely affects human health
- It is a main ingredient in electronic cigarettes and windshield washer liquid
- Using it, you might look cool to some people (but they are pathetic losers)
- Plastic boogers – your snot turns white and is now made of plastic
Ready for the formula? It's CH3CHOHCH2OH
The molecular formula for propylene glycol is C3H8O2. It is a clear and colourless liquid and is non-corrosive.
C3H8O2 can accumulate in your body from the use of shampoo, deodorant, moisturisers and creams, pain medication and a host of food products. So there's probably already enough in there without the use of e-cigs.
E-cigarettes offer you the opportunity to pay money to suck PG directly into the center of your body.
What Should You Do About It?
At best, e-cigarettes are neutral for your health and at worst they are detrimental to your health. How bad for you are they?
You'll need good luck if you are currently using an electronic cigarette! Because the health effects are largely unknown, using an e-cig is a gamble and you'll need all the luck you can get.
Propylene Glycol Reference from the EPA
It looks like a few people have looked into it before. It's surprising there's not a lot of available data as to the effects of inhalation on humans. Shocking!
Check out this Propylene Glycol Reference List from the EPA:
Support:  - Acute Toxicity to Daphnids (Daphnia Magna) under Static Conditions, with Cover Letter Dated 8/28/96 (Sanitized). EPA/OTS; Doc #89960000203S . 1996.
Methoxypropanol, dipropylene glycol methyl ether. S.Hirzel Verlag, P.O.Box 10 10 61, 70009 Stuttgart, Germany, 1997.vii, 142p.Bibl.ref. 1997.
A 2-Year Vapor Inhalation Oncogenicity Study & Evaluation of Hepatic Cellular Proliferation & P450 Enzyme Induction in B6c3f1 Mice W/Cover Letter Dated 06/02/99 (Sanitized). EPA/OTS; Doc #86990000051S . 1999.
2-Year Vapor Inhl Chronic/Oncogenicity Study & Evaluation of Hepatic & Renal Cellular Proliferation, P450 Enzyme Induction & Protein Droplet Nephropathy W/Cover Letter Dated 060299. EPA/OTS; Doc #86990000050 . 1999.
Initial Submission: Letter from Ciba Specialty Chems Inc to Usepa Re Acute Toxicity Studies of Alcopol 0 70pg, Collafix Pp2, & Cfr 5651/Magnafloc 1697, W/Attchmts & Dated 12/23/98. EPA/OTS; Doc #88990000073 . 1999.
Comparative Metabolism and Disposition of Ethylene Glycol Monomethyl Ether and Propylene Glycol Monomethyl Ether in Male Rats with Attachments. EPA/OTS; Doc #86-890001230 . 2000.
Propylene Glycol Monomethyl Ether: Inhalation Teratology Study in Rats and Rabbits. EPA/OTS; Doc #86-890001233 . 2000.
Propylene Glycol Monomethyl Ether: Inhalation Teratology Probe Study in Rats and Rabbits. EPA/OTS; Doc #86-890001232 . 2000.
Evaluation of Propylene Glycol-N-Butyl Ether in an Vitro Chromosomal Aberration Assay Utilizing Chinese Hamster Ovary (Cho) Cells (Final Report) (Sanitized). EPA/OTS; Doc #86-890001243S . 2000.
Evaluation of Propylene Glycol-N-Butyl Ether in the Ames Salmonella/Mammalian-Microsome Bacterial Mutagenicity Assay (Final Report) (Sanitized). EPA/OTS; Doc #86-890001244S . 2000.
Nonlinear Kinetics of Inhaled Propylene Glycol Monomethyl Ether in Fischer 344 Rats Following Single and Repeated Exposures (Final Report) with Attachments. EPA/OTS; Doc #86-890001164 . 2000.
Analysis of Dowanol Cx, a Mixture of Dipropylene Glycol Methyl Ether & Propylene Glycol Isobutyl Ether in the Aquatic Environment (Final Report) (Sanitized). EPA/OTS; Doc #86-890001114S . 2000.
Evaluation of the Acute Dermal Toxicity of Dowanol-Pnb in Rat with Attachments (Sanitized). EPA/OTS; Doc #86-890001250S . 2000.
Evaluation of the Acute Oral Toxicity of Dowanol-Pnb in the Rat (Final Report) (Sanitized). EPA/OTS; Doc #86-890001246S . 2000.
Results of Range Finding Toxicological Test on Three Samples of 4-Tert Octyl Phenol. EPA/OTS; Doc #40-5462011 . 2000.
Blood Pharmacokinetics of Propylene Glycol Methyl Ether and Propylene Glycol Methyl Ether Acetate in Male F-344 Rats after Dermal Application, with Cover Letter Dated 2/10/2000. EPA/OTS; Doc #FYI-OTS-0600-1385 . 2000.
Propylene Glycol Monomethyl Ether: A 13-Week Inhalation Toxicity Study in Rats and Rabbits. EPA/OTS; Doc #86-890001229 . 2000.
Warning for oral solution. AIDS Patient Care STDS 14(9):519-20. 2000.
Odor Evaluation Study on Dowtherm 209 Coolant (Dowanol Pm; Monomethyl Ether of Propylene Glycol) in Humans. EPA/OTS; Doc #86-890001220 . 2000.
Assessment of the Oral Toxicity, Including the Haemolytic Activity of Dowanol-Pnb in the Rat: 14-Day Study with Attachments. EPA/OTS; Doc #86-890001253 . 2000.
Chronic Skin Absorption of Propylene Glycol Methyl Ether (33b) and Dipropylene Glycol Methyl Ether (50b) in Rabbits. EPA/OTS; Doc #86-890001219 . 2000.
Propylene Glycol-N-Butyl Ether: An Acute Vapor Inhalation Study in Fischer 344 Rats (Final Report) with Attachments (Sanitized). EPA/OTS; Doc #86-890001245S . 2000.
Propylene Glycol Monomethyl Ether (Pgme): 21-Day Dermal Study in New Zealand White Rabbits. EPA/OTS; Doc #86-890001162 . 2000.
Propylene Glycol Monomethyl Ether: 2-Week Vapor Inhalation Study in Rats and Mice (Sanitized). EPA/OTS; Doc #86-890001235S . 2000.
Propylene Glycol-N-Butyl Ether: Two-Week Vapor Inhalation Study with Fischer 344 Rats (Final Report) (Sanitized). EPA/OTS; Doc #86-890001260S . 2000.
Subchronic (13-Wk) Dermal Toxicity Study with Propylene Glycol-N-Butyl Ether in Rats (Final Report). EPA/OTS; Doc #86-890001257 . 2000.
Alfons, K. and Engstrom, S. Drug compatibility with the sponge phases formed in monoolein, water, and propylene glycol or poly(ethylene glycol). J Pharm Sci 87(12):1527-30. 1998.
Altaras, N. E. and Cameron, D. C. Metabolic engineering of a 1,2-propanediol pathway in Escherichia coli. Appl Environ Microbiol 65(3):1180-5. 1999.
Altaras, N. E. and Cameron, D. C. Enhanced production of (R)-1,2-propanediol by metabolically engineered Escherichia coli. Biotechnol Prog 16(6):940-6. 2000.
Altaras, N. E., Etzel, M. R., and Cameron, D. C. Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8. Biotechnol Prog 17(1):52-6. 2001.
Andrews, A. H. and Wilkinson, J. Recombinant bovine somatotropin and propylene glycol following glucose injection in treating pregnancy toxaemia. Large Animal Practice; 19 (6).1998.31-33. 1998.
Anon. BIBRA Toxicity Profile of propylene glycol. Govt Reports Announcements & Index (GRA&I), Issue 19, 1996 . 1996.
Anon. Toxicology and Carcinogenesis Studies of 1-Chloro-2-Propanol (Technical Grade) (CAS No. 127-00-4) in F344 Rats and B6C3F1 Mice (Drinking Water Studies). Govt Reports Announcements & Index (GRA&I), Issue 06, 1999 . 1998.
Anonymous. Joint Assessment of Commodity Chemicals No. 33, 1,1-Dichloro-2,2,2-trifluoroethane (HCFC-123) CAS No. 306-83-2. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, 55 pages, 92 references, 1996 . 1996.
Anonymous. Propylenglykol (Aug 1995). TA:Beratergremium fuer umweltrelevante Altstoffe (BUA) PG:25 p YR:1996 IP: VI:166 . 1996.
Anonymous. Dipropylene glycol (December 1993). TA:Beratergremium fuer umweltrelevante Altstoffe (BUA) PG:70 p YR:1996 IP: VI:162 . 1996.
Anonymous. Reproductive toxicology. Propylene glycol. Environ Health Perspect 1997 Feb;105 Suppl 1:231-2 . 1997.
Anonymous. Reproductive toxicology. Propylene glycol monomethyl ether. Environ Health Perspect 1997 Feb;105 Suppl 1:233-4 . 1997.
Anonymous. Toxicological profile for Ethylene Glycol and Propylene Glycol. TA:Agency for Toxic Substances and Disease Registry U.S.Public Health Service PG:249 p YR:1997 IP: VI. 1997.
Anonymous. Reproductive toxicology. 2,2-bis(bromomethyl)-1,3-propanediol. Environ Health Perspect 1997 Feb;105 Suppl 1:271-2 . 1997.
Anonymous. Final report on the safety assessment of Yarrow (achillea millefolium) extract. TA:Int J Toxicol PG:79-84 YR:2001 IP:Suppl 2 VI:20 . 2001.
Anonymous. Final report on the safety assessment of Calendula officinalis extract and calendula officinalis. TA:Int J Toxicol PG:13-20 YR:2001 IP:Suppl 2 VI:20 . 2001.
Anonymous. Final report on the safety assessment of Arnica montana extract and arnica montana. TA:Int J Toxicol PG:1-11 YR:2001 IP:Suppl.2 VI:20 . 2001.
Anonymous. Final report on the safety assessment of Hypericum perforatum extract and hypericum perforatum oil. TA:Int J Toxicol PG:31-9 YR:2001 IP:Suppl 2 VI:20 . 2001.
Aoshima, H. Effects of alcohols and food additives on glutamate receptors expressed in Xenopus oocytes: Specificity in the inhibition of the receptors. Bioscience Biotechnology and Biochemistry; 60 (3).1996.434-438. 1996.
Aouizerate, P., Dume, L., and Astier, A. Ethylene glycol poisoning: Presence of propylene glycol traces, and research of analytic interference due to propylene glycol, in the colorimetric determination of glycolic acid. Journal De Pharmacie Clinique; 15 (Spec.Issue).1996.40-42. 1996.
Appleton, R. E. The new antiepileptic drugs [published erratum appears in Arch Dis Child 1997 Jan;76(1):81]. Arch Dis Child 1996 Sep;75(3):256-62 . 1996.
Araki, Y., Andoh, A., Fujiyama, Y., Takizawa, J., Takizawa, W., and Bamba, T. Short-term oral administration of a product derived from a probiotic, Clostridium butyricum induced no pathological effects in rats. Int J Mol Med 9(2):173-7. 2002.
Arbour, R. B. Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion. Am J Crit Care 8(1):499-506. 1999.
Arellano, A., Santoyo, S., Martn, C., and Ygartua, P. Surfactant effects on the in vitro percutaneous absorption of diclofenac sodium. Eur J Drug Metab Pharmacokinet 23(2):307-12. 1998.
Arellano, A., Santoyo, S., Martin, C., and Ygartua, P. Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels. Eur J Pharm Sci 7(2):129-35. 1999.
Baker, R. C. and Kramer, R. E. Cytotoxicity of short-chain alcohols. Cho, A.K.(Ed.).Annual Review of Pharmacology and Toxicology, Vol.39.Vii+470p.Annual Reviews Inc.: Palo Alto, California, USA.Isbn 0-8243-0439-X; 39 (0).1999.127-150. 1999.
Barber, J. T., Thomas, D. A., Ensley, H. E., and Yatsu, L. Y. Duckweed Diols and Death. Plant Biology '97: 1997 Annual Meetings of the American Society of Plant Physiologists and the Canadian Society of Plant Physiologists, Japanese Society of Plant Physiologists and the Australian Society of Plant Physiologists, Vancouver, British Columbia, Canada, August 2-6, 1997.Plant Physiology (Rockville); 114 (3 Suppl.).1997.124. 1997.
Barratt, M. D. QSARS for the eye irritation potential of neutral organic chemicals. Toxicology in Vitro; 11 (1-2).1997.1-8. 1997.
Basketter, D. A., Chamberlain, M., Griffiths, H. A., Rowson, M., Whittle, E., and York, M. The classification of skin irritants by human patch test. Food and Chemical Toxicology; 35 (8).1997.845-852. 1997.
Basketter, D. A., Gerberick, G. F., and Kimber, I. Strategies for identifying false positive responses in predictive skin sensitization tests. Food and Chemical Toxicology; 36 (4).1998.327-333. 1998.
Bausmith, D. S. and Neufeld, R. D. Soil biodegradation of propylene glycol based aircraft deicing fluids. Water Environment Research; 71 (4).1999.459-464. 1999.
Bennett, G. N. and San, K. Y. Microbial formation, biotechnological production and applications of 1,2-propanediol. Appl Microbiol Biotechnol 55(1):1-9. 2001.
Bjerre, C., Bjork, E., and Camber, O. Bioavailability of the sedative propiomazine after nasal administration in rats. Int.J.Pharm.; VOL 144 ISS Nov 29 1996, P217-224, (REF 22) . 1996.
Blake, D. A., Whikehart, D. R., Yu, H., Vogel, T., and Roberts, D. D. Common cryopreservation media deplete corneal endothelial cell plasma membrane Na+,K+ ATPase activity. Curr Eye Res 15(3):263-71. 1996.
Bobik, T. A., Xu, Y., Jeter, R. M., Otto, K. E., and Roth, J. R. Propanediol utilization genes (pdu) of Salmonella typhimurium: three genes for the propanediol dehydratase. J Bacteriol 179(21):6633-9. 1997.
Bobik, T. A., Havemann, G. D., Busch, R. J., Williams, D. S., and Aldrich, H. C. The propanediol utilization (pdu) operon of Salmonella enterica serovar Typhimurium LT2 includes genes necessary for formation of polyhedral organelles involved in coenzyme B(12)-dependent 1, 2-propanediol degradation. J Bacteriol 181(19):5967-75. 1999.
Bolon, B., Bucci, T. J., Warbritton, A. R., Chen, J. J., Mattison, D. R., and Heindel, J. J. Differential follicle counts as a screen for chemically induced ovarian toxicity in mice: Results from continuous breeding bioassays. Fundamental and Applied Toxicology; 39 (1).1997.1-10. 1997.
Boman, A. and Maibach, H. Influence of Evaporation and Repeated Exposure on the Percutaneous Absorption of Organic Solvents. Elsner, P., Et Al.(Ed.).Current Problems in Dermatology (Basel), Vol.25.Prevention of Contact Dermatitis; International Conference on the Prevention of Contact Dermatitis, Zurich, Switzerland, October 4-7, 1995.X+226p.S.Karger Ag: Basel, Switzerland; New York, New York, USA.Isbn 3-8055-6311-6.; 25 (0).1996.57-66. 1996.
Brayden, D., Creed, E., O'Connell, A., Leipold, H., Agarwal, R., and Leone-Bay, A. Heparin absorption across the intestine: effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Pharm Res 14(12):1772-9. 1997.
Bremmer, D. R., Trower, S. L., Bertics, S. J., Besong, S. A., Bernabucci, U., and Grummer, R. R. Etiology of fatty liver in dairy cattle: effects of nutritional and hormonal status on hepatic microsomal triglyceride transfer protein. J Dairy Sci 83(10):2239-51. 2000.
Breslin, W. J., Cieszlak, F. S., Zablotny, C. L., Corley, R. A., Verschuuren, H. G., and Yano, B. L. Evaluation of the developmental toxicity of inhaled dipropylene glycol monomethyl ether (DPGME) in rabbits and rats. Occup Hyg 1996;2:161-70 . 1996.
Bruyas, J. F., Martins-Ferreira, C., Fieni, F., and Tainturier, D. The effect of propanediol on the morphology of fresh and frozen equine embryos. Equine Vet J Suppl (25):80-4. 1997.
Burkhart, J., Piacitelli, C., Schwegler-Berry, D., and Jones, W. Environmental study of nylon flocking process. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH PART A; 57 (1).1999.1-23.AB - BIOSIS COPYRIGHT: BIOL ABS.Environmental measurements for a variety of gas, particulate, and microbiological agents have been made in order to characterize exposures associated with the nylon flocking process.Of all agents measured, particulate is the predominant exposure.Levels of total particulate ranged from 0.1 to 240 mg/m3 ( x = 11.4 mg/m3).Average respirable particulate was 2.2 mg/m3, ranging from 0.5 to 39.9 mg/m3.Highest levels of particulates were found in the flocking room, and direct reading dust measuremen veral of which were linked directly to the process.Of special interest were elongated respirable particles, which by microscopic analysis, complemented with melting-point determination, were found to be shreds of nylon. 1999.
Cameron, D. C., Altaras, N. E., Hoffman, M. L., and Shaw, A. J. Metabolic engineering of propanediol pathways. Biotechnol Prog 14(1):116-25. 1998.
Carney, E. W., Crissman, J. W., Liberacki, A. B., Clements, C. M., and Breslin, W. J. Assessment of adult and neonatal reproductive parameters in Sprague-Dawley rats exposed to propylene glycol monomethyl ether vapors for two generations. Toxicol Sci 1999 Aug;50(2):249-58 . 1999.
Carney, E. W. and Johnson, K. A. Comparative developmental toxicity of the glycol ether metabolites, methoxyacetic acid and methoxypropionic acid. Teratology 2000 Jun;61(6):454 . 2000.
Chapin, R. E., Sloane, R. A., and Haseman, J. K. The relationships among reproductive endpoints in Swiss mice, using the reproductive assessment by Continuous Breeding database. Fundam Appl Toxicol 1997 Aug;38(2):129-42 . 1997.
Chapin, R. E. and Sloane, R. A. Reproductive assessment by continuous breeding: evolving study design and summaries of ninety studies. Environ Health Perspect 1997 Feb;105 Suppl 1:199-205 . 1997.
Chicu, S. A. and Berking, S. Interference with metamorphosis induction in the marine cnidaria Hydractinia echinata (hydrozoa): A structure-activity relationship analysis of lower alcohols, aliphatic and aromatic hydrocarbons, thiophenes, tributyl tin and crude oil. Chemosphere; 34 (8).1997.1851-1866. 1997.
Chou C-H, S. J., Holler, J., and De Rosa, C. T. Minimal risk levels (MRLs) for hazardous substances. Journal of Clean Technology Environmental Toxicology and Occupational Medicine; 7 (1).1998.1-24. 1998.
Christensen, J. O., Grummer, R. R., Rasmussen, F. E., and Bertics, S. J. Effect of method of delivery of propylene glycol on plasma metabolites of feed-restricted cattle. J Dairy Sci 80(3):563-8. 1997.
Cicolella, A. [Evaluation of risks of glycol ethers for the reproductive health]. Sante Publique 1997 Jun;9(2):157-83 . 1997.
Colin, T., Bories, A., and Moulin, G. Inhibition of Clostridium butyricum by 1,3-propanediol and diols during glycerol fermentation. Appl Microbiol Biotechnol 54(2):201-5. 2000.
Cook, G., Papich, M. G., Roberts, M. C., and Bowman, K. F. Pharmacokinetics of cisapride in horses after intravenous and rectal administration. Am J Vet Res 58(12):1427-30. 1997.
Corley, R. A., Crissman, J. W., Redmond, J. M., McGuirk, R. J., Cieszlak, F. S., and Stott, W. T. Adaptive Metabolic and Pathologic Changes following Chronic Inhalation of Propylene Glycol Monomethyl Ether in Rats and Mice. Occupational Hygiene, Vol.2, Nos.1-6, pages 319-328, 24 references, 1996 AB - The temporal relationships between propylene-glycol-monomethyl-ether (107982) (PGME) induced metabolic and morphological changes in rats and mice which have been chronically exposed to up to 3,000 parts per million (ppm) of PGME vapors were characterized.B6C3F1-mice and F344-rats were exposed to 300, 1,000, or 3,000ppm for 6 hours a day, 5 days a week, for up to 2 years.Results indicated that there is potential for adaptive biochemical and cellular changes in response to chemical exposure to modify the toxicity of PGME in rats and mice.Nearly all inhaled PGME was absorbed, resulting in high systemic levels of PGME.These levels may result in central nervous system depression and the clinically observable sedation of exposed animals.A disruption in male rats was noted in the processing of alpha2micro-globulin resulting in mild degenerative effects in renal tubule epithelial cells.The pronounced sedation of rats and mice exposed to 3,000ppm resolved by the second week of exposure.The induction of O-dealkylase activity in these animals suggests an increase in the potential of metabolized PGME via its major metabolic route to propylene-glycol and then to carbon-dioxide.Exposed animals may also have effectively enhanced PGME metabolism by increasing the number of hepatocytes in response to PGME exposure resulting in the increase in liver weights.Clearly defined, treatment related renal effects were only observed in male rats.The authors conclude that high concentrations of PGME cause an adaptive hepatic response in both sexes of rats and mice that is partially reversed in rats. 1996.
Cornwell, P. A., Barry, B. W., Bouwstra, J. A., and Gooris, G. S. Modes of action of terpene penetration enhancers in human skin; differential scanning calorimetry, small-angle x-ray diffraction and enhancer uptake studies. Int.J.Pharm.; VOL 127 ISS Jan 15 1996, P9-26, (REF 50) . 1996.
Corsi, S. R., Booth, N. L., and Hall, D. W. Aircraft and runway deicers at General Mitchell International Airport, Milwaukee, Wisconsin, USA. 1. Biochemical oxygen demand and dissolved oxygen in receiving streams. Environ Toxicol Chem 20(7):1474-82. 2001.
Corsi, S. R., Hall, D. W., and Geis, S. W. Aircraft and runway deicers at General Mitchell International Airport, Milwaukee, Wisconsin, USA. 2. Toxicity of aircraft and runway deicers. Environ Toxicol Chem 20(7):1483-90. 2001.
Daniel, R., Bobik, T. A., and Gottschalk, G. Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes. FEMS Microbiol Rev 22(5):553-66. 1998.
Davison, S., Benson, C. E., Ziegler, A. F., and Eckroade, R. J. Evaluation of disinfectants with the addition of antifreezing compounds against nonpathogenic H7N2 avian influenza virus. Avian Dis 43(3):533-7. 1999.
De Bortoli, M., Ghezzi, E., Knoppel, H., and Vissers, H. A new test chamber to measure material emissions under controlled air velocity. Environmental Science & Technology; 33 (10).1999.1760-1765. 1999.
Debellefontaine, H., Chakchouk, M., Foussard, J. N., Tissot, D., and Striolo, P. Treatment of organic aqueous wastes: Wet air oxidation and Wet Peroxide Oxidation. Environmental Pollution; 92 (2).1996.155-164. 1996.
Dib, R., Chobert, J. M., Dalgalarrondo, M., and Haertle, T. Secondary structure changes and peptic hydrolysis of beta-lactoglobulin induced by diols. Biopolymers 39(1):23-30. 1996.
Ding, P., Xu, H., Wei, G., and Zheng, J. Microdialysis sampling coupled to HPLC for transdermal delivery study of ondansetron hydrochloride in rats. Biomed Chromatogr 14(3):141-3. 2000.
Doenicke, A., Roizen, M. F., Hoernecke, R., Mayer, M., Ostwald, P., and Foss, J. Haemolysis after etomidate: comparison of propylene glycol and lipid formulations. Br J Anaesth 79(3):386-8. 1997.
Dorr, R. T., Bellamy, W., Liddil, J. D., Baker, A., and Bair, K. W. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des 1998 Oct;13(7):825-35 . 1998.
el-Fiky, M. A. Hyperglycemic effect of a neurotoxic fraction (F3) from Naja haje venom: role of hypothalamo-pituitary adrenal axis (HPA). J Nat Toxins 8(2):203-12. 1999.
Elliott, R. C., Jones, J. R., McElvenny, D. M., Pennington, M. J., Northage, C., Clegg, T. A., Clarke, S. D., Hodgson, J. T., and Osman, J. Spontaneous abortion in the British semiconductor industry: An HSE investigation. Health and Safety Executive [see comments]. Am J Ind Med 1999 Nov;36(5):557-72 . 1999.
Emiliani, S., Van den Bergh, M., Vannin, A. S., Biramane, J., and Englert, Y. Comparison of ethylene glycol, 1,2-propanediol and glycerol for cryopreservation of slow-cooled mouse zygotes, 4-cell embryos and blastocysts. Hum Reprod 15(4):905-10. 2000.
Farshid, A. A., Rajan, A., and Nair, M. K. Ultrastructural pathology of the lymphoid organs in Japanese quail embryos in experimental ochratoxicosis. Indian Veterinary Journal; 73 (12).1996.1225-1230. 1996.
Farshid, A. A. and Rajan, R. Assessment of the cell-mediated immune response of Japanese quails in experimental ochratoxicosis. Indian Veterinary Journal; 73 (11).1996.1117-1121. 1996.
Farshid, A. A., Rajan, A., and Nair, M. K. Ultrastructural pathology of the lymphoid organs in Japanese quail embryos in experimental ochratoxicosis. Journal of Veterinary and Animal Sciences; 27 (1).1998.21-26. 1998.
Gabiga, H., Cal, K., and Janicki, S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system. Int J Pharm 199(1):1-6. 2000.
Gallacher, G. and Maibach, H. I. Is atopic dermatitis a predisposing factor for experimental acute irritant contact dermatitis? Contact Dermatitis; 38 (1).1998.1-4. 1998.
Gao, D. Y., Neff, K., Xiao, H. Y., Matsubayashi, H., Cui, X. D., Bonderman, P., Bonderman, D., Harvey, K., McIntyre, J. A., Critser, J., Miraglia, C. C., and Reid, T. Development of optimal techniques for cryopreservation of human platelets. I. Platelet activation during cold storage (at 22 and 8 degrees C) and cryopreservation. Cryobiology 38(3):225-35. 1999.
Garnier, R. [Acute poisoning with industrial products]. Rev Prat 50(4):377-84. 2000.
Garzon-De la Mora, P., Garcia-Lopez, P. M., Garcia-Estrada, J., Navarro-Ruiz, A., Villanueva-Michel, T., Villarreal-de Puga, L. M., and Casillass-Ochoa, J. Casimiroa edulis seed extracts show anticonvulsive properties in rats. J Ethnopharmacol 68(1-3):275-82. 1999.
George, J. and Murray, E. Toxicological Profile for Ethylene Glycol and Propylene Glycol. Govt Reports Announcements & Index (GRA&I), Issue 05, 1998 . 1997.
Germann, P. G., Ockert, D., and Heinrichs, M. Pathology of the oropharyngeal cavity in six strains of rats: Predisposition of Fischer 344 rats for inflammatory and degenerative changes. Toxicologic Pathology; 26 (2).1998.283-289. 1998.
Gilmore, J. A., Liu, J., Gao, D. Y., and Critser, J. K. Determination of optimal cryoprotectants and procedures for their addition and removal from human spermatozoa. Hum Reprod 1997 Jan;12(1):112-8 . 1997.
Glover, M. L. and Reed, M. D. Propylene glycol: safe diluent that continues to cause harm. Pharmacotherapy; VOL 16 ISS 4 1996, P690-693, (REF 18) . 1996.
Godwin, D. A. and Michniak, B. B. Influence of drug lipophilicity on terpenes as transdermal penetration enhancers. Drug Dev Ind Pharm 25(8):905-15. 1999.
Gotvajn, A. Z. and Zagorc-Koncan, J. Laboratory simulation of biodegradation of chemicals in surface waters: closed bottle and respirometric test. Chemosphere 38(6):1339-46. 1999.
Groning, R. and Kuhland, U. Pulsed release of nitroglycerin from transdermal drug delivery systems. Int J Pharm 193(1):57-61. 1999.
group, Bibra working. Propylene Glycol. TA:Toxicity profile.BIBRA Toxicology International PG:16 p YR:1996 IP: VI. 1996.
group, N. T. P. working. Toxicology and carcinogenesis studies of 1-Chloro-2-Propanol (Technical grade) in F344/N rats and B6C3F1 mice (drinking water studies). TA:National Toxicology Program Technical Report Series PG:264 p YR:1998 IP: VI:477 . 1998.
Guerriero, F. J., Seaman, C. W., Sprague, G. L., Sutton, T. J., and Toseland, C. D. Developmental toxicity in rats treated orally with 2-(2-iodoethyl)-1,3-propanediol diacetate. Toxicologist 2000 Mar;54(1):291-2 . 2000.
Guin, J. D. Contact Dermatitis and Other Contact Reactions. Lieberman, P.And J.A.Anderson (Ed.).Current Clinical Practice: Allergic Diseases: Diagnosis and Treatment.X+402p.Humana Press Inc.: Totowa, New Jersey, USA.Isbn 0-89603-367-8.; 0 (0).1997.233-254. 1997.
Gupta, A. K., Einarson, T. R., Summerbell, R. C., and Shear, N. H. Overview of topical antifungal therapy in dermatomycoses: North American perspective. Drugs; VOL 55 ISS May 1998, P645-674, (REF 447) . 1998.
Gupta, G., Dawn, G., and Forsyth, A. The trend of allergic contact dermatitis in the elderly population over a 15-year period. Contact Dermatitis; 41 (1).1999.48-50. 1999.
Hall, S. and Godwin-Saad, E. Effects of Pollutants on Freshwater Organisms. Water Environment Research; 68 (4).1996.776-784. 1996.
Hattori, T. and Maehashi, H. Increase in Calcium Influx by Propylene Glycol at Mouse Motor Nerve Terminals. In Vitro Toxicology.A Journal of Molecular and Cellular Toxicology, Vol.9, No.4, pages 373-375, 10 references, 1996 . 1996.
Hattori, T. and Maehashi, H. Facilitation of calcium influx by propylene glycol through the voltage- dependent calcium channels in PC12 cells. Res Commun Mol Pathol Pharmacol 105(3):179-84. 1999.
Hattori, T. and Maehashi, H. Rise in intracellular calcium concentration by propylene glycol in PC12 cells. Int J Neurosci 99(1-4):151-7. 1999.
Hattori, T., Maehashi, H., Miyazawa, T., and Naito, M. Enhancement of dopamine release by propylene glycol in PC12 cells. Res Commun Mol Pathol Pharmacol 107(3-4):323-9. 2000.
Havemann, G. D., Sampson, E. M., and Bobik, T. A. PduA is a shell protein of polyhedral organelles involved in coenzyme B(12)-dependent degradation of 1,2-propanediol in Salmonella enterica serovar typhimurium LT2. J Bacteriol 184(5):1253-61. 2002.
Heylings, J. R., Clowes, H. M., Cumberbatch, M., Dearman, R. J., Fielding, I., Hilton, J., and Kimber, I. Sensitization to 2,4-dinitrochlorobenzene: influence of vehicle on absorption and lymph node activation. Toxicology 109(1):57-65. 1996.
Ho, H. O., Chen, L. C., Lin, H. M., and Sheu, M. T. Penetration enhancement by menthol combined with a solubilization effect in a mixed solvent system. J Control Release 51(2-3):301-11. 1998.
Hostynek, J. J. and Magee, P. S. Fragrance allergens: Classification and ranking by QSAR. Toxicology in Vitro; 11 (4).1997.377-384. 1997.
Huang, K., Rudolph, F. B., and Bennett, G. N. Characterization of methylglyoxal synthase from Clostridium acetobutylicum ATCC 824 and its use in the formation of 1, 2- propanediol. Appl Environ Microbiol 65(7):3244-7. 1999.
Imamura, S., Nozawa, I., Imamura, M., and Murakami, Y. Pathogenesis of experimental aural cholesteatoma in the chinchilla. ORL J Otorhinolaryngol Relat Spec 61(2):84-91. 1999.
Inoue, K., Nakazawa, K., Fujimori, K., Ohno, Y., Takanaka, A., Itagaki, H., Kato, S., Kobayashi, T., and Kuroiwa, Y. Evaluation of stinging-inducing chemicals using cultured neuronal cells: An electrophysiological approach. Toxicology in Vitro; 10 (4).1996.455-462. 1996.
Ishidate, M. Jr, Miura, K. F., and Sofuni, T. Chromosome aberration assays in genetic toxicology testing in vitro. Mutation Research; 404 (1-2).1998.167-172. 1998.
Ishiwata, H., Nishijima, M., Fukasawa, Y., Ito, Y., and Yamada, T. Evaluation of the contents of BHA, BHT, propylene glycol, and sodium saccharin in foods and estimation of daily intake based on the results of official inspection in Japan in fiscal year 1994. Journal of the Food Hygienic Society of Japan; 39 (2).1998.89-100. 1998.
Jaiswal, J., Poduri, R., and Panchagnula, R. Transdermal delivery of naloxone: ex vivo permeation studies. Int J Pharm 179(1):129-34. 1999.
Janik, M., Kleinhans, F. W., and Hagedorn, M. Overcoming a permeability barrier by microinjecting cryoprotectants into zebrafish embryos (Brachydanio rerio). Cryobiology 2000 Aug;41(1):25-34 . 2000.
Jewgenow, K., Penfold, L. M., Meyer, H. H., and Wildt, D. E. Viability of small preantral ovarian follicles from domestic cats after cryoprotectant exposure and cryopreservation. J Reprod Fertil 112(1):39-47. 1998.
Johnson, C. L., Pechonick, E., Park, S. D., Havemann, G. D., Leal, N. A., and Bobik, T. A. Functional genomic, biochemical, and genetic characterization of the Salmonella pduO gene, an ATP:cob(I)alamin adenosyltransferase gene. J Bacteriol 183(5):1577-84. 2001.
Johnson, W. Final report on the safety assessment of Propylene Glycol (PG) Dicaprylate, PG Dicaprylate-Dicaprate, PG Dicocoate, PG Dipelargonate, PG Isostearate, PG Laurate, PG Myristate, PG Oleate, PG Oleate SE, PG Dioleate, PG Dicaprate, PG Diisostearate, and PG Dilaurate. International Journal of Toxicology; 18 (Suppl.2).1999.35-52. 1999.
Jones, T. D. On 'toxicity equivalent factors' and 'relative potency' to account for differential toxicity and carcinogenicity: Concerns about uncommon effects of dose in animal experiments and environmental exposures to humans. Environmetrics; 9 (5).1998.525-539. 1998.
Kang, L., Jun, H. W., and McCall, J. W. Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport. Int J Pharm 206(1-2):35-42. 2000.
Karami, K. and Beronius, P. On iontophoretic delivery enhancement: ionization and mobility of lidocaine hydrochloride in propylene glycol. Int.J.Pharm.; VOL 168 ISS Jun 8 1998, P85-95, (REF 17) . 1998.
Karran, G. and Legge, M. Non-enzymatic formation of formaldehyde in mouse oocyte freezing mixtures. Hum Reprod 11(12):2681-6. 1996.
Kataoka, M., Sasaki, M., Hidalgo, A. R., Nakano, M., and Shimizu, S. Glycolic acid production using ethylene glycol-oxidizing microorganisms. Biosci Biotechnol Biochem 65(10):2265-70. 2001.
Kedzierewicz, F., Darme, X., Etienne, A., Lemut, J., Hoffman, M., and Maincent, P. Preparation of silicone microspheres by emulsion polymerization: application to the encapsulation of a hydrophilic drug. J Microencapsul 15(2):227-36. 1998.
Kellner, D. L. Sorption of the Aircraft Deicing Fluid Component Methyl-Benzotriazole in Soil. /u0014 . 1999.
Kerai, M. Dj, Waterfield, C. J., and Timbrell, J. A. The Effects of Propylene Glycol on Paracetamol Toxicity in Hamsters. Annual Progress of the British Toxological Society, Warwick, England, Uk, March 24-26, 1997.Human & Experimental Toxicology; 16 (7).1997.407. 1997.
Kimber, I., Dearman, R. J., and Basketter, D. A. Estimation of relative skin sensitization potency using the local lymph node assay. Annual Congress of the British Toxicology Society, Stoke on Trent, England, Uk, April 18-21, 1999.Yhuman & Experimental Toxicology; 18 (8).1999.524. 1999.
Kiriyama, A., Sugahara, M., Yoshikawa, Y., Kiso, Y., and Takada, K. Bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs. Biopharm.Drug Dispos.; VOL 17 ISS Mar 1996, P125-134, (REF 20) . 1996.
Kolloffel, W. J., Weekers, L. E., and Goldhoorn, P. B. Pharmacokinetics of propylene glycol after rectal administration. Pharm World Sci 18(3):109-13. 1996.
Kowalczyk, C. L., Stachecki, J. J., Schultz, J. F., Leach, R. E., and Armant, D. R. Effects of alcohols on murine preimplantation development: Relationship to relative membrane disordering potency. Alcoholism Clinical and Experimental Research; 20 (3).1996.566-571. 1996.
Kruszewski, F. H., Walker, T. L., and Dipasquale, L. C. Evaluation of a human corneal epithelial cell line as an in vitro model for assessing ocular irritation. Fundamental and Applied Toxicology; 36 (2).1997.130-140. 1997.
Krzymien, M., Day, M., Shaw, K., Mohmad, R., and Sheehan, S. The role of feed composition on the composting process. II. Effect on the release of volatile organic compounds and odours. Journal of Environmental Science and Health Part a Toxic-Hazardous Substances & Environmental Engineering; 34 (6).1999.1369-1396. 1999.
Kucherenko, Y. U. and Moiseev, V. A. The use of 1H-NMR spectroscopy and refractometry for investigation of the distribution of nonelectrolytes of N-alcohol series between human red blood cells and extracellular medium. Membr Cell Biol 13(5):633-44. 2000.
Kulkarni, A. S. and Hopfinger, A. J. Membrane-interaction QSAR analysis: Application to the estimation of eye irritation by organic compounds. Pharmaceutical Research (New York); 16 (8).1999.1245-1253. 1999.
Kusunoki, J., Kai, A., Yanagawa, Y., Monma, C., Shingaki, M., Obata, H., Itoh, T., Ohta, K., Kudoh, Y., and Nakamura, A. [Biochemical and molecular characterization of Salmonella ser. enteritidis phage type 1 isolated from food poisoning outbreaks in Tokyo]. Kansenshogaku Zasshi 73(5):437-44. 1999.
Kuznetsova, N., Chi, S. L., and Leikin, S. Sugars and polyols inhibit fibrillogenesis of type I collagen by disrupting hydrogen-bonded water bridges between the helices. Biochemistry 37(34):11888-95. 1998.
LaDou, J. and Rohm, T. The international electronics industry. Int J Occup Environ Health 1998 Jan-Mar;4(1):1-18 . 1998.
Laitinen, J. Biomonitoring of technical grade 1-alkoxy-2-propanol acetates by analysing urinary 2-alkoxypropionic acids. Sci Total Environ 1997 Jun 20;199(1-2):31-9 . 1997.
Laitinen, J., Liesivuori, J., and Savolainen, H. Biological monitoring of occupational exposure to 1-methoxy-2-propanol. J Chromatogr B Biomed Sci Appl 694(1):93-8. 1997.
LaKind, J. S., McKenna, E. A., Hubner, R. P., and Tardiff, R. G. A review of the comparative mammalian toxicity of ethylene glycol and propylene glycol. Crit Rev Toxicol 29(4):331-65. 1999.
Lanigan, R. S. Special report: reproductive and developmental toxicity of ethylene glycol and its ethers. Int J Toxicol 1999;18(Suppl 2):53-67 . 1999.
Lansdown, A. B. and Taylor, A. Zinc and titanium oxides: promising UV-absorbers but what influence do they have on the intact skin? Int.J.Cosmet.Sci.; VOL 19 ISS 4 1997, P167-172, (REF 10) . 1997.
Larrucea, E., Arellano, A., Santoyo, S., and Ygartua, P. Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm 52(2):113-9. 2001.
Lee, B. J., Lee, T. S., Cha, B. J., Kim, S. H., and Kim, W. B. Percutaneous absorption and histopathology of a poloxamer-based formulation of capsaicin analog. Int.J.Pharm.; VOL 159 ISS Dec 15 1997, P105-114, (REF 21) . 1997.
Lee, B. J., Cui, J. H., Parrott, K. A., Ayres, J. W., and Sack, R. L. Percutaneous absorption and model membrane variations of melatonin in aqueous-based propylene glycol and 2-hydroxypropyl-beta-cyclodextrin vehicles. Arch Pharm Res 21(5):503-7. 1998.
Leone-Bay, A., Leipold, H., Agarwal, R., Rivera, T., and Baughman, R. A. Evolution of an oral heparin dosing solution. Drugs Future; VOL 22 ISS Aug 1997, P885-891, (REF 22) . 1997.
Leppik, I. E. Role of new and established antiepileptic drugs. Epilepsia 1998;39 Suppl 5:2-6 . 1998.
Levang, A. K., Zhao, K., and Singh, J. Effect of ethanol/propylene glycol on the in vitro percutaneous absorption of aspirin, biophysical changes and macroscopic barrier properties of the skin. Int J Pharm 181(2):255-63. 1999.
Li, B., Pinch, H., and Birt, D. F. Influence of vehicle, distant topical delivery, and biotransformation on the chemopreventive activity of apigenin, a plant flavonoid, in mouse skin. Pharm Res 13(10):1530-4. 1996.
Li, B. and Birt, D. F. In vivo and in vitro percutaneous absorption of cancer preventive flavonoid apigenin in different vehicles in mouse skin. Pharm.Res.; VOL 13 ISS Nov 1996, P1710-1715, (REF 9) . 1996.
Liesivuori, J., Laitinen, J., and Savolainen, H. Rat model for renal effects of 2-alkoxyalcohols and their acetates. Arch Toxicol 73(4-5):229-32. 1999.
Lin, S. Y., Duan, K. J., and Lin, T. C. Microscopic FT-IR/DSC system used to simultaneously investigate the conversion process of protein structure in porcine stratum corneum after pretreatment with skin penetration enhancers. Methods Find Exp Clin Pharmacol 18(3):175-81. 1996.
Liu, C. J., Ueda, M., Kosaka, S., Hirata, T., Yokomise, H., Inui, K., Hitomi, S., and Wada, H. A newly developed solution enhances thirty-hour preservation in a canine lung transplantation model. J Thorac Cardiovasc Surg 112(3):569-76. 1996.
Longo, D. L., Duffey, P. L., Kopp, W. C., Heyes, M. P., Alvord, W. G., Sharfman, W. H., Schmidt, P. J., Rubinow, D. R., and Rosenstein, D. L. Conditioned immune response to interferon-gamma in humans. Clin Immunol 90(2):173-81. 1999.
Loskutoff, N. M., Simmons, H. A., Goulding, M., Thompson, G., De Jongh, T., and Simmons, L. G. Species and individual variations in cryoprotectant toxicities and freezing resistances of epididymal sperm from African antelope. Animal Reproduction Science; 42 (1-4).1996.527-535. 1996.
Louik, C., Frumkin, H., Ellenbecker, M. J., Goldman, R. H., Werler, M. M., and Mitchell, A. A. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. J Occup Environ Med 42(7):693-703. 2000.
Machate, T. and Kettrup, A. Spectrophotometric method for the determination of 1,2-propylene glycol. Fresenius' Journal of Analytical Chemistry; 360 (1).1998.137-138. 1998.
Mahadevan, M. M., McIntosh, Q., Miller, M. M., Breckinridge, S. M., Maris, M., and Moutos, D. M. Formaldehyde in cryoprotectant propanediol and effect on mouse zygotes. Hum Reprod 1998 Apr;13(4):979-82 . 1998.
Mailhes, J. B., Young, D., and London, S. N. 1,2-propanediol-induced premature centromere separation in mouse oocytes and aneuploidy in one-cell zygotes. Biol Reprod 57(1):92-8. 1997.
Code: 3, 6
Malandain, H. and Cano, Y. An Enzymatic Assay for the Emergency Diagnosis of Propylene Glycol Intoxication. 48th Annual Meeting of the American Association for Clinical Chemistry, Inc., Chicago, Illinois, USA, July 28-August 1, 1996.Clinical Chemistry; 42 (6 Part 2).1996.S213. 1996.
Mallidis, C., Phelan, D., Coles, M., and Jones, G. Does the composition of propane-1,2-diol alter over time? J Assist Reprod Genet 13(1):53-5. 1996.
Malonne, H., Fontaine, J., and Moes, A. In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water. Biol Pharm Bull 23(5):627-31. 2000.
Manganaro, A. M. and Wertz, P. W. The effects of permeabilizers on the in vitro penetration of propranolol through porcine buccal epithelium. Mil Med 161(11):669-72. 1996.
Massaad, C., Entezami, F., Massade, L., Benahmed, M., Olivennes, F., Barouki, R., and Hamamah, S. How can chemical compounds alter human fertility? Eur J Obstet Gynecol Reprod Biol 100(2):127-37. 2002.
Matthews, H. B. Chemical Metabolism and Toxicokinetics. Crisp Data Base National Institutes Of Health . 1996.
Mauldin, R. E., Goodall, M. J., Volz, S. A., Griffin, D. L., Petty, E. J., and Johnston, J. J. Zinc phosphide residue determination in alfalfa (Medicago sativa). Journal of Agricultural and Food Chemistry; 45 (6).1997.2107-2111. 1997.
McCain, W. C., Lee, R., Johnson, M. S., Whaley, J. E., Ferguson, J. W., Beall, P., and Leach, G. Acute oral toxicity study of pyridostigmine bromide, permethrin, and DEET in the laboratory rat. Journal of Toxicology and Environmental Health; 50 (2).1997.113-124. 1997.
McClanahan, S., Hunter, J., Murphy, M., and Valberg, S. Propylene glycol toxicosis in a mare. Veterinary and Human Toxicology; 40 (5).1998.294-296. 1998.
Mead, C. and Pentreath, V. W. Evaluation of toxicity indicators in rat primary astrocytes, C6 glioma and human 1231N1 astrocytoma cells: Can gliotoxicity be distinguished from cytotoxicity? Archives of Toxicology; 72 (6).1998.372-380. 1998.
Medlicott, N. J., Foster, K. A., Audus, K. L., Gupta, S., and Stella, V. J. Comparison of the effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J Pharm Sci 87(9):1138-43. 1998.
Meshitsuka, S., Inoue, M., Seki, A., Koeda, T., and Takeshita, K. Screening of urine by one-dimensional and pulsed-field gradient two- dimensional 1H NMR spectroscopy: intoxication by propylene glycol in an infant patient. Clin Chim Acta 279(1-2):47-54. 1999.
Mirochnick, M., Clarke, D. F., McNamara, E. R., and Cabral, H. Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets. Am J Health Syst Pharm 57(19):1775-7. 2000.
Mitchell, H. L. Toxicity of Tolyltriazole to Gram-Positive Coccus Microorganisms. /u0019 . 2000.
Miyoshi, S., Pate, J. L., and Palmquist, D. L. Effects of propylene glycol drenching on energy balance, plasma glucose, plasma insulin, ovarian function and conception in dairy cows. Anim Reprod Sci 68(1-2):29-43. 2001.
Mochimaru, M. and Sakurai, H. Effects of organic solvents and tentoxin on enzyme-bound ATP synthesis in isolated chloroplast coupling factor 1. Photosynthesis Research; 57 (3).1998.305-315. 1998.
Mori, T., Sakimoto, M., Kagi, T., and Sakai, T. Secondary alcohol dehydrogenase from a vinyl alcohol oligomer-degrading Geotrichum fermentans; stabilization with Triton X-100 and activity toward polymers with polymerization degrees less than 20. 1998.
Morshed, K. M., Jain, S. K., and McMartin, K. E. Propylene glycol-mediated cell injury in a primary culture of human proximal tubule cells. Toxicol Sci 46(2):410-7. 1998.
Moser, K., Kriwet, K., Froehlich, C., Kalia, Y. N., and Guy, R. H. Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res 18(7):1006-11. 2001.
Mukaida, T., Wada, S., Takahashi, K., Pedro, P. B., An, T. Z., and Kasai, M. Vitrification of human embryos based on the assessment of suitable conditions for 8-cell mouse embryos. Hum Reprod 13(1O):2874-9. 1998.
Mura, P., Faucci, M. T., Bramanti, G., and Corti, P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci 9(4):365-72. 2000.
Murakami, T., Yoshioka, M., Yumoto, R., Higashi, Y., Shigeki, S., Ikuta, Y., and Yata, N. Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. J Pharm Pharmacol 50(1):49-54. 1998.
Mushrush, G. W., Basak, S. C., Slone, J. E., Beal, E. J., Basu, S., Stalick, W. M., and Hardy, D. R. Computational Study of the Environmental Fate of Selected Aircraft Fuel System Deicing Compounds. Journal of Environmental Science and Health.Part A: Environmental Science and Engineering and Toxic and Hazardous Substance Control, Vol.A32, No.8, pages 2201-2211, 17 references, 1997 . 1997.
Neurath, G., Franke, S., Francke, W., and Marquardt, H. Mutagenicity of Trichlorinated Dipropylether Isomers. 39th Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology, Mainz, Germany, March 17-19, 1998.Naunyn-Schmiedeberg's Archives of Pharmacology; 357 (4 Suppl.).1998.R142. 1998.
Newton, H., Fisher, J., Arnold, J. R., Pegg, D. E., Faddy, M. J., and Gosden, R. G. Permeation of human ovarian tissue with cryoprotective agents in preparation for cryopreservation. Hum Reprod 13(2):376-80. 1998.
Niazy, E. M. Differences in penetration enhancing effect of Azone through excised rabbit, rat, hairless mouse, guinea pig and human skins. Int.J.Pharm.; VOL 130 ISS Mar 22 1996, P225-230, (REF 24) . 1996.
Noddegaard, F. and Kennaway, D. J. A method of achieving physiological plasma levels of melatonin in the chicken by oral administration. J Pineal Res 27(3):129-38. 1999.
Nordic steering group for assessment of health effects of, chemicals. Health effects of selected chemicals 4-5. 2,2ï-Oxydiethanol (Diethylene glycol). TA:Nord PG:317-41 YR:1999 IP: VI:15 . 1999.
Ogier de Baulny, B., Labbe, C., and Maisse, G. Membrane integrity, mitochondrial activity, ATP content, and motility of the European catfish (Silurus glanis) testicular spermatozoa after freezing with different cryoprotectants. Cryobiology 39(2):177-84. 1999.
Ogiso, T., Niinaka, N., and Iwaki, M. Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci 85(1):57-64. 1996.
Oh, S. Y., Jeong, S. Y., Park, T. G., and Lee, J. H. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. J Control Release 51(2-3):161-8. 1998.
Oude Elferink, S. J., Krooneman, J., Gottschal, J. C., Spoelstra, S. F., Faber, F., and Driehuis, F. Anaerobic conversion of lactic acid to acetic acid and 1, 2-propanediol by Lactobacillus buchneri. Appl Environ Microbiol 67(1):125-32. 2001.
Palmer, R., Godwin, D., and McKinney, P. Transdermal Kinetics of a Mercurous Chloride Beauty Cream an in Vitro Human Skin Analysis. Annual Meeting of the North American Congress of Clinical Toxicology, Orlando, Florida, USA, September 9-15, 1998.Journal of Toxicology Clinical Toxicology; 36 (5).1998.528-529. 1998.
Panchagnula, R., Salve, P. S., Thomas, N. S., Jain, A. K., and Ramarao, P. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin. Int J Pharm 219(1-2):95-105. 2001.
Parker, M. G., Fraser, G. L., Watson, D. M., and Riker, R. R. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med 28(1):81-4. 2002.
Patro, N., Mishra, S. K., Chattopadhyay, M., and Patro, I. K. Neurotoxicological effects of deltamethrin on the postnatal development of cerebellum of rat. Journal of Biosciences (Bangalore); 22 (2).1997.117-130. 1997.
Peleg, O., Bar-Oz, B., and Arad, I. Coma in a premature infant associated with the transdermal absorption of propylene glycol. 1998.
Pendergrass, S. M. Determination of glycols in air: Development of sampling and analytical methodology and application to theatrical smokes. American Industrial Hygiene Association Journal July-Aug.1999, Vol.60, No.4, p.452-457.Illus.23 ref. 1999.
Peng, L. and Nimni, M. E. Delivery of erythromycin to subcutaneous tissues in rats by means of a trans-phase delivery system. J Pharm Pharmacol 51(10):1135-41. 1999.
Perkins, M. A., Osborne, R., and Johnson, G. R. Development of an in vitro method for corrosion testing. Fundamental and Applied Toxicology; 31 (1).1996.9-18. 1996.
Perkins, M. A., Osborne, R., Rana, F. R., Ghassemi, A., and Robinson, M. K. Comparison of in vitro and in vivo human skin responses to consumer products and ingredients with a range of irritancy potential. Toxicological Sciences; 48 (2).1999.218-229. 1999.
Pilgram, G. S., Engelsma-van Pelt, A. M., Koerten, H. K., and Bouwstra, J. A. The effect of two azones on the lateral lipid organization of human stratum corneum and its permeability. Pharm Res 17(7):796-802. 2000.
Pillard, D. A. and Dufresne, D. L. Toxicity of formulated glycol deicers and ethylene and propylene glycol to Lactuca sativa, Lolium perenne, Selenastrum capricornutum, and Lemna minor. Archives of Environmental Contamination and Toxicology; 37 (1).1999.29-35. 1999.
Pistoor, F. Hm, Rambukkana, A., Kroezen, M., Lepoittevin, J. P., Bos, J. D., Kapsenberg, M. L., and Das, P. K. Novel predictive assay for contact allergens using human skin explant cultures. American Journal of Pathology; 149 (1).1996.337-343. 1996.
Poppe, L. and Retey, J. Kinetic investigations with inhibitors that mimic the posthomolysis intermediate in the reactions of coenzyme-B12-dependent glycerol dehydratase and diol dehydratase. Eur J Biochem 245(2):398-401. 1997.
Price-Carter, M., Tingey, J., Bobik, T. A., and Roth, J. R. The alternative electron acceptor tetrathionate supports B12-dependent anaerobic growth of Salmonella enterica serovar typhimurium on ethanolamine or 1,2-propanediol. J Bacteriol 183(8):2463-75. 2001.
Proniuk, S., Dixon, S. E., and Blanchard, J. Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms. Pharm Dev Technol 6(3):469-76. 2001.
Qatibi, A. I., Bennisse, R., Jana, M., and Garcia, J. L. Anaerobic degradation of glycerol by Desulfovibrio fructosovorans and D. carbinolicus and evidence for glycerol-dependent utilization of 1,2-propanediol. Current Microbiology; 36 (5).1998.283-290. 1998.
Qian, W., Amin, R. H., and Shichi, H. Cytotoxic metabolite of acetaminophen, N-acetyl-p-benzoquinone imine, produces cataract in DBA2 mice. J Ocul Pharmacol Ther 15(6):537-45. 1999.
Rayburn, W., Christensen, D., and Gonzalez, C. Neurobehavior effects in four strains of mice offspring exposed prenatally to alprazolam (XanaxÑ). Am J Obstet Gynecol 2001 Dec;185(6 Pt 2):S184 . 2001.
Reddy, I. K., Khan, M. A., Wu, W. M., and Bodor, N. S. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 12(2):159-67. 1996.
Rice, P. J., Anderson, T. A., and Coats, J. R. The Use of Vegetation to Enhance Biodegradation and Reduce Offsite Movement of Aircraft Deicers. 212th American Chemical Society National Meeting, Orlando, Florida, USA, August 25-29, 1996.Abstracts of Papers American Chemical Society; 212 (1-2).1996.Agro 54. 1996.
Rice, P. J. and Coats, J. R. The Use of Plants for Reducing the Environmental Impact of De-Icing Agents Au - Anderson Ta. 212th American Chemical Society National Meeting, Orlando, Florida, USA, August 25-29, 1996.Abstracts of Papers American Chemical Society; 212 (1-2).1996.Agro 97. 1996.
Rondon, M. R. and Escalante-Semerena, J. C. High levels of transcription factor RpoS (sigma S) in mviA mutants negatively affect 1,2-propanediol-dependent transcription of the cob/pdu regulon of Salmonella typhimurium LT2. FEMS Microbiol Lett 169(1):147-53. 1998.
Rosenkranz, M., Rosenkranz, H. S., and Klopman, G. Intercellular communication, tumor promotion and non-genotoxic carcinogenesis: relationships based upon structural considerations. Mutat Res 1997 Nov 28;381(2):171-88 . 1997.
Saini, M., Dash, S., and Nagpaul, J. P. Hematological Alterations in Propylene Glycol-Dosed Female Rats Are Minimal. Veterinary and Human Toxicology, Vol.38, No.2, pages 81-85, 27 references, 1996 . 1996.
Schenker, M. B. Reproductive health effects of glycol ether exposure in the semiconductor industry. Occup Hyg 1996;2(1-6):367-72 . 1996.
Schneider, I. M., Dobner, B., Neubert, R., and Wohlrab, W. Evaluation of drug penetration into human skin ex vivo using branched fatty acids and propylene glycol. Int.J.Pharm.; VOL 145 ISS Dec 6 1996, P187-196, (REF 32) . 1996.
Schoenberg, T., Veltman, S., and Switzenbaum, M. Kinetics of anaerobic degradation of glycol-based type I aircraft deicing fluids. Biodegradation 12(1):59-68. 2001.
Schramke, J. A., Murphy, S. F., Doucette, W. J., and Hintze, W. D. Prediction of aqueous diffusion coefficients for organic compounds at 25êC. Chemosphere; 38 (10).1999.2381-2406. 1999.
Schwarb, F. P., Imanidis, G., Smith, E. W., Haigh, J. M., and Surber, C. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 16(6):909-15. 1999.
Seay, R. E., Graves, P. J., and Wilkin, M. K. Comment: possible toxicity from propylene glycol in lorazepam infusion. Ann.Pharmacother.; VOL 31 ISS May 1997, P647-648, (REF 11) . 1997.
Senthilmohan, S. T., McEwan, M. J., Wilson, P. F., Milligan, D. B., and Freeman, C. G. Real time analysis of breath volatiles using SIFT-MS in cigarette smoking. Redox Rep 6(3):185-7. 2001.
Shepherd, M. F. and Felt-Gunderson, P. A. Diarrhea associated with lorazepam solution in a tube-fed patient. Nutr.Clin.Pract.; VOL 11 ISS 3 1996, P117-120, (REF 13) . 1996.
Shimoi, K., Okada, H., Furugori, M., Goda, T., Takase, S., Suzuki, M., Hara, Y., Yamamoto, H., and Kinae, N. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 438(3):220-4. 1998.
Siddiqui, A., Yasmeen, A., Shaharyar, S., and Mariam, T. Neural and endocrine consequences of perinatal exposure to benzodiazepine. J Reprod Fertil Abstr Ser 1998 Jul;(21):30 . 1998.
Singhai, A., Jain, S., and Jain, N. K. Evaluation of piroxicam injection. Indian J.Pharm.Sci.; VOL 59 ISS 6 1997, P306-311, (REF 9) . 1997.
Skaare, A. B., Rolla, G., and Barkvoll, P. The influence of triclosan, zinc or propylene glycol on oral mucosa exposed to sodium lauryl sulphate. Eur J Oral Sci 105(5 Pt 2):527-33. 1997.
Sloan, K. B., Taylor, H. E., and Hamilton, J. C. Alcohol flux and effect on the delivery of theophylline from propylene glycol. Int.J.Pharm.; VOL 156 ISS Oct 10 1997, P17-26, (REF 14) . 1997.
Son, W. Y., Park, S. E., Lee, K. A., Lee, W. S., Ko, J. J., Yoon, T. K., and Cha, K. Y. Effects of 1,2-propanediol and freezing-thawing on the in vitro developmental capacity of human immature oocytes. Fertil Steril 1996 Dec;66(6):995-9 . 1996.
Sonoda, T., Fukunaga, K., Tashiro, S., Ohba, K., and Sugimoto, T. Carbamazepine-induced cardiovascular abnormalities in chick embryos. Teratology 1996 Oct;54(4):14A . 1996.
Squillante, E., Needham, T., Maniar, A., Kislalioglu, S., and Zia, H. Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin. Eur J Pharm Biopharm 46(3):265-71. 1998.
Sun, W. Q., Meng, M., Kumar, G., Geelhaar, L. A., Payne, G. F., Speedie, M. K., and Stacy, J. R. Biological denitration of propylene glycol dinitrate by Bacillus sp. ATCC 51912. Applied Microbiology and Biotechnology; 45 (4).1996.525-529. 1996.
Swan, S. H. and Forest, W. Reproductive risks of glycol ethers and other agents used in semiconductor manufacturing. Occup Hyg 1996;2(1-6):373-85 . 1996.
Taguchi, K., Fukushima, S., Yamaoka, Y., Takeuchi, Y., and Suzuki, M. Enhancement of propylene glycol distribution in the skin by high purity cis-unsaturated fatty acids with different alkyl chain lengths having different double bond position. Biol Pharm Bull 22(4):407-11. 1999.
Takahashi, O. and Oishi, S. Disposition of orally administered bisphenol A in pregnant rats and the placental transfer to fetuses. J Toxicol Sci 1999 Oct;24(4):297 . 1999.
Takahashi, O. and Oishi, S. Disposition of orally administered 2,2-Bis(4-hydroxyphenyl)propane (Bisphenol A) in pregnant rats and the placental transfer to fetuses. Environ Health Perspect 2000 Oct;108(10):931-5 . 2000.
Takeuchi, Y., Miyawaki, K., Kamiyabu, S., Fukushima, S., Yamaoka, Y., Kishimoto, S., Taguchi, K., Masai, H., and Kamata, Y. Use of electroporation to accelerate the skin permeability enhancing action of oleic acid. Biol Pharm Bull 23(7):850-4. 2000.
Tanojo, H., Bouwstra, J. A., Junginger, H. E., and Bodde, H. E. In vitro human skin barrier modulation by fatty acids: skin permeation and thermal analysis studies. Pharm.Res.; VOL 14 ISS Jan 1997, P42-49, (REF 20) . 1997.
Tanojo, H., Junginger, H. E., and Bodde, H. E. In vivo human skin permeability enhancement by oleic acid: transepidermal water loss and Fourier-transform infrared spectroscopy studies. J.Controlled Release; VOL 47 ISS Jul 7 1997, P31-39, (REF 44) . 1997.
Tanojo, H. and Junginger, H. E. Skin permeation enhancement by fatty acids. J.Disper.Sci.Tech.; VOL 20 ISS 1-2 1999, P127-138, (REF 25) . 1999.
Tanojo, H., Boelsma, E., Junginger, H. E., Ponec, M., and Bodde, H. E. In vivo human skin permeability enhancement by oleic acid: laser Doppler velocimetry study. J.Controlled Release; VOL 58 ISS Mar 8 1999, P97-104, (REF 39) . 1999.
Taylor, S. L. and Dormedy, E. S. The Role of Flavoring Substances in Food Allergy and Intolerance. Taylor, S.L.(Ed.).Advances in Food and Nutrition Research, Vol.42.Ix+278p.Academic Press, Inc.: San Diego, California, USA; London, England, Uk.Isbn 0-12-016442-6.; 42 (0).1998.1-44. 1998.
Tenjarla, S. N., Puranajoti, P., Kasina, R., and Mandal, T. Terbutaline transdermal delivery: preformulation studies and limitations of in vitro predictive parameters. J.Pharm.Pharmacol.; VOL 48 ISS Nov 1996, P1138-1142, (REF 10) . 1996.
Tice, R. R., Nylander-French, L. A., and French, J. E. Absence of systemic in vivo genotoxicity after dermal exposure to ethyl acrylate and tripropylene glycol diacrylate in Tg.AC (v-Ha-ras) mice. Environ Mol Mutagen 1997;29(3):240-9 . 1997.
Tobimatsu, T., Kajiura, H., Yunoki, M., Azuma, M., and Toraya, T. Identification and expression of the genes encoding a reactivating factor for adenosylcobalamin-dependent glycerol dehydratase. J Bacteriol 181(13):4110-3. 1999.
Tsang, A. W. and Escalante-Semerena, J. C. cobB function is required for catabolism of propionate in Salmonella typhimurium LT2: evidence for existence of a substitute function for CobB within the 1,2-propanediol utilization (pdu) operon. J Bacteriol 178(23):7016-9. 1996.
Tsang, A. W., Horswill, A. R., and Escalante-Semerena, J. C. Studies of regulation of expression of the propionate (prpBCDE) operon provide insights into how Salmonella typhimurium LT2 integrates its 1,2- propanediol and propionate catabolic pathways. J Bacteriol 180(24):6511-8. 1998.
Tsuchiya, Y. and Kanabus-Kaminska, J. M. Identification and Quantification of Volatile Organic Compounds Using Systematic Single-Ion Chromatograms. Wang, W., J.L.Schnoor and J.Doi (Ed.).Astm Stp, 1261.Volatile Organic Compounds In the Environment; Symposium, Montreal, Quebec, Canada, April 11-13, 1994.291p.Astm (American Society for Testing and Materials): Philadelphia, Pennsylvania, USA.Isbn 0-8031-2048-6.; 0 (1261).1996.127-138. 1996.
Tsutsumi, K., Obata, Y., Takayama, K., Loftsson, T., and Nagai, T. Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate. Drug Dev Ind Pharm 24(8):757-62. 1998.
Tuo, J., Loft, S., Thomsen, M. S., and Poulsen, H. E. Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: reduction by CYP2E1 inhibition. Mutat Res 368(3-4):213-9. 1996.
Valenta, C. and Wedenig, S. Effects of penetration enhancers on the in-vitro percutaneous absorption of progesterone. J Pharm Pharmacol 49(10):955-9. 1997.
van den Abbeel, E., van der Elst, J., van der Linden, M., and van Steirteghem, A. C. High survival rate of one-cell mouse embryos cooled rapidly to -196 degrees C after exposure to a propylene glycol-dimethylsulfoxide- sucrose solution. Cryobiology 34(1):1-12. 1997.
van den Wollenberg, L., Pellicaan, C. H., and Muller, K. [Intoxication with propylene glycol in two horses.]. Tijdschr Diergeneeskd 125(17):519-23. 2000.
Varon, J. and Marik, P. Etomidate and propylene glycol toxicity. J Emerg Med 16(3):485. 1998.
Veltman, S., Schoenberg, T., and Switzenbaum, M. S. Alcohol and acid formation during the anaerobic decomposition of propylene glycol under methanogenic conditions. Biodegradation 9(2):113-8. 1998.
Verschuuren, H. G. Toxicological Studies with Propylene Glycol n-Butyl Ether. Occupational Hygiene, Vol.2, Nos.1-6, pages 311-318, 6 references, 1996 . 1996.
Villard, P. H., Seree, E. M., Re, J. L., De Meo, M., Barra, Y., Attolini, L., Dumenil, G., Catalin, J., Durand, A., and Lacarelle, B. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA. Toxicol Appl Pharmacol 1998 Feb;148(2):195-204 . 1998.
Vincent, R., Rieger, B., Subra, I., and Poirot, P. Exposure Assessment to Glycol Ethers by Atmosphere and Biological Monitoring. Occupational Hygiene, Vol.2, Nos.1-6, pages 79-90, 14 references, 1996 . 1996.
Vitkova, Z., Gardavska, K., and Cizmarik, J. Study of local anaesthetics. Part 139. Preformulation study of N-[2-(2- heptyloxyphenylcarbamoyloxy)-ethyl] dimethylammonium chloride. Acta Pharm Hung 66(6):253-7. 1996.
Voziyan, P. A. and Fisher, M. T. Polyols induce ATP-independent folding of GroEL-bound bacterial glutamine synthetase. Arch Biochem Biophys 397(2):293-7. 2002.
W, H. O. Evaluation of Certain Food Additives and Contaminants. Who Technical Report Series; 0 (868).1997.I-Viii, 1-69. 1997.
Wada, H., Liu, C. J., Hirata, T., Bando, T., and Kosaka, S. Effective 30-hour preservation of canine lungs with modified ET-Kyoto solution. Ann Thorac Surg; 61(4):1099-105 1996 . 1996.
Wahlberg, J. E. and Boman, A. Prevention of Contact Dermatitis from Solvents. Elsner, P., Et Al.(Ed.).Current Problems in Dermatology (Basel), Vol.25.Prevention of Contact Dermatitis; International Conference on the Prevention of Contact Dermatitis, Zurich, Switzerland, October 4-7, 1995.X+226p.S.Karger Ag: Basel, Switzerland; New York, New York, USA.Isbn 3-8055-6311-6.; 25 (0).1996.57-66. 1996.
Walter, D., Ailion, M., and Roth, J. Genetic characterization of the pdu operon: use of 1,2-propanediol in Salmonella typhimurium. J Bacteriol 179(4):1013-22. 1997.
Wang, G. and Bai, N. Structure-activity relationships for rat and mouse DL50 of miscellaneous alcohols. Chemosphere; 36 (7).1998.1475-1483. 1998.
Warbrick, E. V., Dearman, R. J., Basketter, D. A., and Kimber, I. Local lymph node assay responses to (chloro)methylisothiazolinone: Influence of vehicle. Annual Congress of the British Toxicology Society, Stoke on Trent, England, Uk, April 18-21, 1999.Yhuman & Experimental Toxicology; 18 (8).1999.526. 1999.
Wester, R. C., Hui, X., Landry, T., and Maibach, H. I. In vivo skin decontamination of methylene bisphenyl isocyanate (MDI): soap and water ineffective compared to polypropylene glycol, polyglycol- based cleanser, and corn oil. Toxicol Sci 48(1):1-4. 1999.
Who. Evaluation of certain food additives and contaminants. 884: Forty-ninth report of the Joint FAO-WHO Expert Committee on Food Additives. Who Technical Report Series; 0 (884).1999.1-96. 1999.
Wieslander, G., Norback, D., and Lindgren, T. Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects. Occup Environ Med 58(10):649-55. 2001.
Williams, S. P., O'Brien, S., Whitmore, K., Purcell, W. M., Cookson, M. R., Mead, C., Pentreath, V. W., and Atterwill, C. K. An in vitro neurotoxicity testing scheme: Evaluation of cytotoxicity determinations in neural and non-neural cells. In Vitro Toxicology; 9 (1).1996.83-92. 1996.
Wilson, K. C., Reardon, C., and Farber, H. W. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 343(11):815. 2000.
Wolkoff, P. and Nielsen, P. A. A new approach for indoor climate labeling of building materials-emission testing, modeling, and comfort evaluation. Atmospheric Environment; 30 (15).1996.2679-2689. 1996.
Wormser, U., Kohen, R., Moor, E. V., Eldad, A., Gal, R., Nyska, A., and Brodsky, B. Noninvasive procedure for in situ determination of skin surface aspartic proteinase activity in animals; implications for human skin. Arch Dermatol Res 289(12):686-91. 1997.
Woycik, C. L. and Walker, P. C. Correction and comment: possible toxicity from propylene glycol in injectable drug preparations. Ann Pharmacother 31(11):1413. 1997.
Wrzesinski, C. L., Feeney, W. P., Feely, W. F., and Crouch, L. S. Dermal penetration of 4"-(epi-methylamino)-4"-deoxyavermectin B1a benzoate in the rhesus monkey. Food and Chemical Toxicology; 35 (10-11).1997.1085-1089. 1997.
Xu, D., Dhillon, A. S., Abelmann, A., Croft, K., Peters, T. J., and Palmer, T. N. Alcohol-related diols cause acute insulin resistance in vivo. Metabolism 47(10):1180-6. 1998.
Zamir, G., Bloom, A. I., and Reissman, P. Prevention of intestinal adhesions after laparotomy in a rat model--a randomized prospective study. Res Exp Med (Berl) 197(6):349-53. 1998.
Ziv, G., Shem-Tov, M., and Ascher, F. Combined effect of ampicillin, colistin and dexamethasone administered intramuscularly to dairy cows on the clinico-pathological course of E. coli-endotoxin mastitis. Veterinary Research (Paris); 29 (1).1998.89-98. 1998.
Electronic cigarette UK
Nicole Aune: I think we're going to go ahead and get started.
So, hello everybody.
Thank you all so much for coming out today, and we may have a few more trickling in, but, um, I just wanted to thank you guys for just taking time out of your evening to come here.
My name is Nicole Aune.
I am a program manager with the Montana Tobacco Use Prevention Program.
I oversee the policy and cessation work.
Um, and we're really here today because there is a new product on the market and it's really captured the attention of our youth and it is the most commonly used tobacco product among our high school students in Montana, and that's E-cigarettes.
So there's a lot of mis-information out there about E-cigarettes and, and it's a confusing thing.
Um, there's a lot of questions and, depending on who you talk to, you're getting different answers.
So, we're here today, um, to hopefully answer those questions for you and give you all the facts and information for you to go out and then talk to your kids and other young people about, about the facts and share this information with others.
We're going to go into what we're going to cover today, so we have some awesome speakers and we're going to be covering what E-cigarettes are.
Um, looking at how many, how many kids in Montana are actually using them.
The why are kids actually using these products.
Why, why are they so into them, and the health dangers that, the health risks associated with E-cigarettes.
Um, and we're also going to talk about how the tobacco industry targets kids with these products, and then mention what you can do.
And we have an excellent line-up of speakers.
Kris Minard: All right.
So Nicole mentioned this is mostly for adults right now, although it's very important kids know about this too.
But this particular um, presentation is, is geared for you.
We'll talk about Montana youth trends and um, let you know more about what electronic cigarettes are, their appeal to youth and then what's actually in the E Juice.
Every time we give a presentation we have to remind people we're talking about tobacco products and tobacco is still the leading cause of preventable death in the United States, killing almost a half a million people every year, which is the same as three fully-loaded 747's crashing every day, with no survivors.
So, if something like that happened, I think people would really take up, take notice and we, we need to remember we still have a lot of, we've done some great work on tobacco, but we have a long way to go.
So, as far as Montana youth trends go, we have great data, stretching back into the early 90's from the Montana Youth Risk Behavior Survey.
Our high school students are asked every other year, um, about their risky behaviors and how much they participate in them.
And, as you can see, these are the kids who say they have every tried smoking cigarettes, even one or two puffs.
We've got a nice trend down from the 90's.
We're at about 39% of our high school students who say they've even tried using tobacco.
These are the students we call current users.
The CDC says if a student responds that they've smoked a cigarette in the last 30 days, then we're going to call them current users.
A lot of people might think that Montana has more smokers on average than the rest of the country, but our, our students have really much um, kept up with the national average all through these last 20+ years.
However, you can see in 2015, 13% of our high school students say they smoked cigarettes and only 11% um, in the nation said they are, so we are above the national average there.
Then we've got these guys, these fruity-flavored, cheap, inexpensive um, cigars, cigarillos, that are kids have, have noticed and, and started using.
We are well above the national average at about 13% compared to 10.
Still a little bit of a decline, but nothing like, you know, it hasn't been as high as the cigarette use, but it's right at 12.
6%, which is pretty, I mean, they're both basically 13%.
Here's where we stand out.
Our smokeless tobacco.
Still 12% of our high school students say they use smokeless, um, snoose, chew, and ah, compared to the national average of 7.
3%, so our high school boys are huge users.
One in five of our high school boys report using smokeless tobacco, fourth highest prevalence of use in the country.
Our girls also have the fourth highest prevalence of use, but it's at a much lower um, prevalence, 4.
So here are all three of the traditional tobacco products.
You can see they're all at about the same level in 2015.
So now we have these guys, these electronic cigarettes.
Well, they all basically deliver nicotine.
There are a very few that don't have some of the E Juice, has zero nicotine in it, but by far most deliver nicotine and they almost all have lithium.
Well, I don't know any that don't have a lithium battery.
They look like lots of different things.
Some look like cigarettes.
Some look like marking pens.
The one on the right, I say kind of looks like a mini lunar lander, and they're just constantly changing.
These things are evolving practically daily.
We also have um, electronic cigarettes we call mods that, these are the products that people typically drip the E-Juice into and they create the great big huge, we say vapor and vaping, but it's really not a vapor, it's an aerosol.
There are tiny particles of metals and, and it's actually an aerosol.
You can see someone even ingeniously made a E-cigarette out of a Coke can.
But they all basically have a mouth piece and someplace to put the E-Juice, whether it's already contained and in a cartomizer or if it's a tank that you have to fill, or if it's an atomizer that you drip onto a cotton swab with E-Juice.
Then they have the heating element, which is the atomizer which heats up, so there's no combustion as with cigarettes.
There's nothing burning.
It just heats up it and creates this, this aerosol in the lithium battery.
Here's a video that NJOY has for anybody to watch on the Internet about how to vape.
(Video) This is NJOY's vape pen.
You picked it up off the shelf or got it in the mail, but it might be intimidating.
We're here to help.
If you're ready to vape watch on.
Part One: Assembling the Vape Pen.
First, you're going to need a bottle of E Liquid, like this.
You can buy NJOY E Liquid wherever you purchased your vape pen.
Next, make sure the battery is detached from the tank.
Don't try to fill the tank with E Liquid when it's attached to the battery.
Unscrew the mouthpiece from the tank.
Open your E Liquid.
NJOY E Liquids are in bottles with child resistant caps.
So to open it, you'll need to push down on the cap as you turn it.
You don't want E Liquid in the center tube.
So when you fill your tank, tilt it and drip the E Liquid down the side.
You can check the milliliter amount by the markings on the side of the tank.
Remember to keep E Liquid away from your skin.
If you happen to get some E Liquid on your hands, make sure to wash them immediately.
We also recommend that you have different tanks for different flavors of E Liquid and that you discard any tank after about two weeks of regular use, depending on how you vape.
Changing your tank will assure that your vapor always tastes great.
Once you fill the tank, screw the mouthpiece back on.
Make sure the mouthpiece is on tight, then screw the tank on to the battery piece.
Now you're ready to vape.
Part Two: How to Vape.
Your pen comes activated right out of the box.
To deactivate your vape or to reactivate it, quickly press the button five times in a row like this.
The LED light flashes five times when your vape pen changes state.
When your vape is activated, put your lips to the mouthpiece.
Inhale as you press the button, and just like that you're vaping.
Part Three: Charging.
The LED light will flash 10 times during use when you need to charge your vape pen.
To charge, simply unscrew the battery from the tank and into the USB charger.
To preserve the battery, don't charge it in a place that's too hot or too cold.
You'll know it's charged when the LED light goes off.
Kris Minard: Anything, time for a little audience interaction.
Anything kind of catch you off guard on, on that one? Anything kind of noticeable? __: Wash your hands.
KM: (Laughter) If you get any of this E Juice on your hands, wash them immediately.
It's okay to inhale it into your lungs, but by golly, if you get it on your hands, wash it off.
Well, nicotine absorbs through everything and um, Dr.
Shepard will talk to us more about the effects of nicotine.
All right, um, gimmicks, there are lots of gimmicks.
The industry, the tobacco industry has had gimmicks for years.
Coupons and products, give aways and things like this, and make no mistake, the tobacco industry is invested in electronic cigarettes.
Yes, there are mom and pop vape shops, but RJ Reynolds, Phillip Morris, Lorillard are all into, into these products.
blu is one that you may have seen ads for on T.
These are what they call the starter kits, and this particular thing costs about $75.
00 a couple of years ago.
I don't know what they cost now.
I would think that the price has gone down.
They look like a cigarette.
They charge right in these cases and their gimmick is each case has a little wireless transistor radio in it, a radio wave, that if you turn this on, this is, this it'll, this is what it will do.
If you're within 50 feet of another person who has one of these.
So they want you to know who's around, who can you go buddy up with, turn it into a social experience again, and um, find somebody, you know, there's somebody around who's using this.
Let's find out who they are.
They also do this if they're within 50 feet of a place that sells the refill cartridges.
So, that's their, that's their gimmick on, on these.
The I Phone case.
It's all set up.
It's got it's own battery and ah, I think this is for ah, I'm not sure, I think it was an I Phone 5, but it's got a mouthpiece.
You can screw your own mouthpiece into the top and, and vape away.
They want to appeal to the environmentally conscious folks.
Our landfills are being filled by these batteries, these empty cartridges.
You know, a lot of really bad toxins and, and pollutants.
So they say, send us your old products and for every 50 old cartridges or old lithium batteries, whatever you send us, we'll give you so many points to buy our products.
So it never ends.
Ah, this woman is going to show you how to use blu and a couple of the, of the other products.
(Video) Um, and this is a blu disposable.
We're going to pull the little seal off of here.
Pull the little rubber cap off and puff.
That's it, nice and simple.
Now the blu starter kit has um, two batteries, five cartomizers and a charger.
These are re-changeable.
Um, this same concept.
Screw the closed cartomizer.
Everything you need is mixed up in here already.
Screw it on and again puff.
Nice and simple.
Another company we carry Smoke Stick, same, same principle.
We have a disposable.
You have an E, the starter kit.
Again, screw it on.
That, as you can tell, is a little bit more vapor than the blu gave me.
Kris Minard: So she had a lot of quick hits of nicotine right there and you can tell she kind of liked that Smoke Stick brand, because it created a little bit more, more vapor.
Um, we'll talk a little bit about these mods.
Um, the people build these themselves, and you can learn all about them on the Internet.
There are people who have their own YouTube channels that show you how to create these things, and they take great pride in creating the coils, and how many, how many turns and twists you have in them, um, relative to how many ohms it's going to produce, and you want to heat it up just.
It's all supposed to be red when it heats up and you put the cotton wick between it and that's what you pour the E Juice onto.
This is an RDA, re-build able dripping atomizer, and this is a mod that has fully computerized.
This whole set costs about $140.
00 here locally.
The battery is another $80.
I did not purchase it, and you can set it to all sorts of different levels to decide how hot you want it to get, how much vapor your, how much aerosol you want to create, and, um, all these little buttons help you.
We'll just pass this stuff around so you all can, can look at it.
There's a great tobacco prevention specialist out, out east who told me, she likes to put things in pencil kits and pass them around and see if people can figure out what's really a pencil and a marker, and what's really a, an E-cigarette, and I said that is a great idea.
So I copied her and it's pretty impressive.
Take a look through this pencil kit, see if you can pick out the E-cigarettes.
This is the fellow who's got one of the YouTube stations or channels and he's got over four million views on, they call them clouds making this big huge cloud with a, with a mod.
So now let's talk about teen vaping and why, why our kids are so, so interested in them.
The 2015 Youth Risk Behavior for their first time asked the question, "Have you ever tried an electronic cigarette and in the last 30 days how many times have you used one?" And you can see by the description they couldn't just say an E-cigarette, they had to define it so that the kids would know what they're talking about, because they're called so many different things.
I mean now you might just hear the word vapes, um, but the responses in Montana really caught us off guard and we were alarmed.
Fifty-one percent of our high school students said they tried them compared to 45% in the rest of the country, which is also huge.
This is what the percentage of people, the high school students who have tried them, broken down by male and female, so not a big difference between the two.
Boys typically have riskier behavior than girls, but you can see it increases with grade level.
A, every year you have more kids using these products.
And granted by 12th grade, some people are 18.
There's no question.
It would not be illegal for them.
Another reason, as Nicole has pointed out, why it would be great to have 21 be the age for using tobacco.
There would be no question.
There are no 21 year olds in high school.
Not in Montana.
They don't fund them.
And this is a question of whether they're current users.
Have they used one in the last 30 days.
So 30% of our high school students said they were current users.
Almost one in three.
And here's that breakdown.
Same, same thing.
Pretty close to the same, but still more boys, and again the same kind of transition from nine through twelfth grade, increasing each, each grade level.
So here are the three traditional tobacco products and then the E-cigarettes in green.
It's kind of a visual deal that boy, twice as many kids, more than twice as many kids are using this product and are smoking.
So anybody who tells you, oh it's just the kids who are smokers who are using this product, that's not true, and this shows you that.
Here's a breakdown by groups.
Um, the state averages of cigarette smokers and vapers, um, on the left and then some of our middle schools actually take the very same Youth Risk Behavior Survey, so those that do have showed us that, wow, twice as many middle school students are vaping as are smoking.
NAR, our Native Americans on a reservation, so that is the only group who are smoking cigarettes is still higher than vaping, but, but not much.
NAU, our Native American's in an urban setting, big difference.
NPA, Non-Public Accredited schools.
A lot of your private religious schools, um, like Central in Butte, Central in Billings.
ALT, those are alternative schools.
That's where our risk takers are and we know that there are huge issues there, and we've got a few projects that we're working on, but boy we, we need to do a lot of work there.
SWD, our Students With Disabilities.
So they're attracting all, all users.
Yale had a great study a few years ago, where they asked 5,400 young people who did vape, what's cool about it? What do they think makes them cool? They were not surprised by the answer, the flavors.
We've all seen and heard, and you're going to hear more from Sara tonight about the flavors, but they were taken back by the fact that kids said we can do vape tricks with them.
So vape tricks.
We're going to show issue, show you a few videos from on-line about what they're doing with these products.
(Video) What's up guys.
We're here at Flawless Vape Shop in Anaheim Hills, California for the 8th Trick Qualified __________________________.
(Music) Ricky was sad.
He just won the 8th Trick Qualifier for the BC Cog Championship.
How do you feel? I'm stoked Still a little nervous? Yeah.
(Laughter) What did you do to prepare for this competition? I vape every day because I work in a vape shop, so.
What vape shop do you work at? Vaper Hub.
Would you like to thank any of your sponsors today? Of course.
Got to thank LindaLace, Good Vibes, Vape Socks, Native Wakes of course, you know.
Good Vibes is my sponsor too.
Good Vibes is awesome.
(Laughter) So before you go, ah, do a signature trick for us.
Kris Minard: Um, anything catch you off guard? Anything kind of impressed you with that? __: The sponsorships.
They have sponsors.
It's like NASCAR and these are young kids.
I mean, he, he was probably 18 or 20.
To me he looked like he was 16 or so, but he said he vaped every day.
I mean, what is he doing to his lungs.
You have to practice a lot to, ah, when you see the next ones you'll, you'll be impressed.
(Video) Kris Minard: I just wanted to show you that girls are doing this as we know.
How'd you like to be the little brother pushed through the aerosol there? The last one is the, oh __: ________________ Is there an odor to it? Kris Minard: There is a slight odor to it, but that's a really good question because someone asked last night, are they using marijuana in these things? And they are, they are.
__: Something like for the feel um, my parents said on the clothing Kris Minard: Oh, can't smell the clothing, right.
Definitely not like tobacco.
There, there is an odor, but the thing about marijuana, is if they are using marijuana, there is no distinctive marijuana odor with these, so someone could be vaping pot right in front of you, um, and you wouldn't know it.
So, but, but, they say there is not much of an odor with these, but I have smelled bubble gum.
I have smelled some of the flavors, when we have done some experiments with, with bottles.
Um, oh yeah, this, this guy, I think this is the one that use.
Oh, you'll want to go back and then that one is a video.
This guy is a real professional.
(Video) Kris Minard: So, you can see.
There's a challenge to them.
There's a competition.
Um, this guy won $10,000, making as big of a cloud as he could possibly could.
So, there are competitions all around the country.
I've not heard of any in Montana, but you know how we are, a little bit behind other states sometimes on things.
We'll hope, we'll hope that we don't get any here, but there's money, there's challenge and kids get good at it.
They take pride in it and who knows what they're doing to their lungs.
So, we often hear well it's just a harmless water vaper.
Well, it's really not.
In fact, there isn't water in these things.
The three main ingredients are propylene glycol, which is something that we use in the theatre in fog machines, and it's generally recognized as safe as an edible, um, chemical.
But that doesn't mean that it's safe for our, for our lungs.
You know, eating something and inhaling something are totally different.
I often say it's okay to eat a peanut, but if you inhale a peanut, you're in trouble.
The flavorings are another thing that's typically in, in the E Juice and nicotine.
Um, and these have not been regulated by the FDA, so some have been found to contain all sorts of carcinogens as well as other toxic chemicals.
Um, the carcinogens on the left, Acetaldehyde, Benzene, Formaldehyde is created as the E-cigarette heats up and, and, so it's actually the heating of the E Juice that creates the Formaldehyde.
Nickel, Nitrosamines, um, and then other toxins, other irritants.
A Diacetyl is an ingredient that has added to the flavorings to help make the flavorings work better.
And you may have heard of popcorn lung.
People who were working in microwave popcorn factories were getting this irreversible lung disease, and they finally figured out it was from the Diacetyl.
Well, Diacetyl is in a lot of E Juice.
I have, I always say if you have to dress like this to work with this product and develop this product in a hazemat suit, then why on earth would anybody want to be putting it into their lungs? Congress did pass a Child Nicotine Prevention Act because a teaspoon can kill a child.
In fact, there was a young toddler who died just before Christmas a couple of years ago.
He got into his parent's E Juice, so, um, now they do have to have child-resistant tops.
Poison Control Center calls have grown exponentially.
In 2014 they increased from one a month to 215 a month for exposure to, to nicotine.
These, this is a little bit deceiving because the 2015 and 2016 data isn't complete on this.
I've been looking for better, updated charts, but, um, it's been a major increase for Poison Center Control calls.
And then you also heard about these exploding lithium batteries.
Um, the industry will tell you, oh it's user error.
You know, it's always user error, but I read an article about a man who opened a package and it blew up.
You know, he wasn't even using them.
We have a, had a young student in Missoula who was vaping and ended up losing four teeth and I really, I mean that was a very traumatic experience.
He had a really hard time getting back to school.
I mean, you can imagine.
It caused a fire on the couch he was sitting on.
So, not good.
This is an example.
Watch the guy standing at the counter on the right.
(Video) Kris Minard: Huge vap, you know plume of, of aerosol and he had to take off his pants and you, you saw the burns ahead of time.
So that's the end of my presentation and we have an, um, question and answer session.
So if you have some questions, we'll do that at, at the very end.
But thanks a lot for coming and thanks for listening, and if I can help you in any way, let me know.
Kathy Rogers: Research suggests that compared to adults, teens value reward more than consequence.
And we kind of all know that, but that is really an integral part of brain development in adolescents.
It is part of what gets them to grow up and leave home.
To go on the adventure of leaving the security of a household where somebody feeds them and clothes them, and takes care of their needs, and goes out to where they're going to have to figure it out.
And so it's, it's an important part of development, but it is also is what makes them take the risks that they do.
Brain development takes a long time, sort of from age 12 to age 25.
And so at 18 and 19, when these kids legally can do a lot of things, they still don't have a very mature brain.
They think they do and if you think back, you thought you did.
And then you got a little older and you realized your parents were not nearly as stupid as you thought they were.
And we hear that said all the time, but it really is true and there's no way to explain it as we grow up.
You can say it to your kids and they nod and think you're full of it, but it's really the truth.
So it, brain maturation moves in really slow waves.
It starts at the base of your brain and kind of moves forward in very basic functions, so it starts with your vision, what you see, and then movement, and then fundamentally how you process things.
The more complicated executive functions.
So this front part of your brain, which is the last part that really puts together, if I jump off of this very tall building, I may break my legs.
And the other part of it says, yeah, but won't it be really cool if I don't.
That part takes a long time to come together, and so there's all these different parts of the brain that you're going to hear talked about as, as more of the issues of brain development go on.
You're going to hear them talk about your hippocampus, which is part of your memory.
The frontal areas set goals.
They weigh agendas and risk and that frontal part is really important.
Um, head injuries, a lot of frontal injuries impact how well we do our executive functions and this is sort of a side comment, but the whole business of concussion relates to what happens when you're constantly impacting that frontal area, which becomes your consequence setting goals, agenda, risk assessment area.
Um, so ultimately development allows us to balance our impulse and desire and our self interest and put that together with ethics and rules, and to put all of that together.
But it takes time and you can have a kid who will say, I know I shouldn't, but they still will until they get on the other side of that fence.
If you think of teen decision making like an equation, where consequences aren't given the weight they should be, rewards weigh more heavily than they should, and where being friends throws the equation off any more.
So that plastic part of your brain really looks at thrill seeking, risk taking, and I don't have a graph to show you, but when you look at higher risk and lower risk and then age, the ones who enjoy it the most are 16 to 17 year olds.
They just, that high risk is like a really good reward, and it's interesting because at 18 and 21 it starts to drop, but it doesn't get down to a level less than when you're 10 years old till you're 26 years old.
So, there's a long time where that is all really important.
Most long-term drug use, alcohol, tobacco, nicotine, starts in adolescence.
And we all recognize that.
Teens do know they're mortal.
They can estimate risk, often over-estimating risk.
They simply value the reward so much more heavily and the more risk they take, if the reward is good, is perceived as a better payout.
And what helps them add to the risk? Doing something with their friends.
So when you look at kids who are learning to drive, there's lots of good valid studies that show.
If you put a kid in a car with an adult, their parent, they will drive beautifully.
They take Driver's Ed, they do really well, and as long as they are in the car with the adult, they're great.
You put one person in the car their age and all of a sudden they run through the red light.
You put two or three kids in the car with them and suddenly it's what can we do? Where can we race? Why? Because there's this huge reward of doing these things, taking these risks with their friends.
So, when you're looking at kids related to cigarette smoking, vaping, it's the same thing.
And so one of the key questions I always ask kids when I'm interviewing them, is do any of your friends vape? Because if you ask them directly, you may or may not get a straight answer, but they don't have any problem telling you if their friends do.
And that's a really good way to kind of come in through the back door when you want to find out what's going on.
Because if their friends are vaping, you can bet that for them it's a greater opportunity, even if they think they're only going to do it once.
So, what their friends do does make a really big difference.
Now, this time of taking all these risks is important.
They need to do this.
It doesn't make them obnoxious, although sometimes it feels like it does when you're the parent.
Um, but that's partly again what gets them to learn how to be independent and on their own.
So adolescence brings a peak in brain sensitivity to dopamine, which is a neurotransmitter, that kind of primes you for reward.
And it fires off the reward circuits.
So anything that improves and effects dopamine is something that they like, and nicotine will effect that as does marijuana and so these sort of spark that area and kids go, oh that felt good.
And feeling good is something you want to do.
Believe it or not, texting fires off that part of your brain, which is why those ridiculous texts of what'ch doing.
Where're you going to be? Not sure.
And yet they're just addicted to it.
They literally fire off that little bit of dopamine over and over again, which is a little pleasure center.
Um, for those of you are old enough, if you remember what it was like to get a letter in the mail and you would wait for the mailman to come.
It's the same thing.
It just didn't happen every five seconds.
So that's part of the difficulty and again, anything that will allow them to get there.
Teen brains, neuro networks are being pruned, and so they're still in that developmental phase.
And it's really interesting, teens prefer teens.
So the things you say do make a difference, but they search out their friends and that's, those people are their investment in the future.
They're not going to spend their life living with you.
You guys are their mentors/directors, but they know you and you're not exciting any more.
Their friends are exciting and that's where they want to be.
So again, who they spend time with and we're back to, what makes me feel good? What's exciting? Um, you guys have the statistics and will probably go over them, so I'm not going to take about the percentages of kids who are using E-cigarettes.
But what I will tell you is, for child, for kids, it's not a reduction of harm.
They use E-cigarettes and they talk about it for adults as a reduction of harm, getting them off of cigarettes.
It doesn't do that for kids.
It becomes the gateway.
It addicts them to nicotine, and we know from both human studies and mouse models, that at the developmental point in your brain that you are when you're a teen, your brain is more plastic and nicodine, nicotine is far more addicting.
We don't know why.
We just know it is.
And it's that developmental phase.
We also know that the various products like nicotine and marijuana at that stage long term will affect brain function.
So when you were talking about the different products that are in there.
So nicotine poisoning, what does it look like? Vomiting, sweating, dizziness, increased heart rate, lethargy, seizures, breathing difficulty, um, it's a neural stimulant at low doses, but at high doses it's a depressant, and it really gets them into trouble.
A couple of things that you need to know and that parents should share with each other; anti smoking actions by parents are a strong predictor of non-smoking in teens.
Anti tobacco opinions, anti vaping opinions and discussions with parents are factors that protect kids against tobacco, even if a parents smokes.
So even if you're a parent who does smoke, the very fact that you say no, makes a huge difference.
The bottom line is, is that you want to make the risk and the reward enough like the reward for not doing this, greater than the reward for doing it, and because nicotine's so addicting, you've got to find ways to sort of them, it's like the toddler thing.
You have to distract them over here.
You keep them busy with other things that are rewarding and fun for them whether it's school or trips with friends that you get to help plan and organize.
But it's pretty basic and it's pretty simple and I can go through all of the neurochemistry and, and all of the brain development doesn't mean anything.
The bottom line is, they like what feels good and what you have to do is find things that make them feel better and make it new and exciting and just sort of distract them until their brain gets to that point and then you also make it clear that this isn't something that you want them to do.
But that's not what you harp on all the time.
You just do the distraction.
That's my line.
Robert Shepard: Um, all right.
I entitled this Nicotine, Safe or Dangerous because I was up at the Legislature trying to get them to increase the tobacco tax, the bill supported by the Governor and Cancer Society and Heart Association, to increase the tobacco tax and ah, they were going to include E-cigarettes on that increase, and actually I was flabbergasted, is the best way to put it, at some of the claims that were made by the E-cigarette proponents about the safety of E-cigarettes and the safety of nicotine.
So, since nicotine is the predominant ingredient in all of the E-cigarette liquids that are set out, I wanted to talk a little bit tonight about nicotine.
Now, before we get to there, we can talk about tobacco and several different oranis, several different kind of categories.
Obviously, there's combustible tobacco, cigarettes, cigars, pipes, and those, those things have a completely different of chemistry.
After all, they're, they're burning, they're burning at a very low temperature really, so they create all kinds of chemicals that get into the air, and that creates all the second-hand smoke and other stuff which is the primary motivation for second-hand smoke laws.
Ah, but we're not going to really talk about combustible tobacco tonight.
You've got your various forms of spit tobacco.
I like to refer to it as spit tobacco to make sure that it's overly glamorized.
Um, but in any case, you've got the various forms of spit tobacco and they also have their own set of chemicals, but they're not heated.
They have chemicals that also that occur a lot during the curing process from the way the tobacco industry cures it, which creates a lot of extra stuff in the, in the leaf beyond just the tobacco plant.
And then lastly we have the E-cigarettes which you've heard about it, and they're not really combustible, but they're not exactly like ah, non-combustible chewing tobacco products because they are heated, and that also has a potential to create different chemicals.
Um, so, and I want to focus a little bit on nicotine now because, 90, somewhere around 97, 99% of all E-cigarette capsules and liquids that are sold are sold with nicotine in them.
So they talk about all the other stuff that goes on, but it really has to do with the nicotine.
So, is nicotine safe? Is it beneficial? Is it addictive? So let's kind of explore some of that.
First of all, there, the way the body works is most of the cells in our body have little tiny receptors on them.
You can consider the receptive would be a lock.
A molecule, a chemical will come by and insert itself into that lock and that creates, causes the cell to do something.
That's the way hormones work, whether they're thyroid hormones or testosterone or estrogen or any of the other, you know, cortisone, any of the other, ah, hormones around the body all work by attaching to a receptor on a cell.
And each cell will have tens of thousands of receptors on it.
It's hard to believe something so small can have that many receptors and there will be dozens of different kinds of receptors on every cell.
Some of these receptors then in the body are triggered by nicotine.
That's how nicotine does what it does.
So nicotine will glom on to, you know, insert itself as a key into that lock and then tell the cell to do something.
And they're really high in concentration in the brain, which should come as no surprise.
Secondly, there are a lot in the lungs and there's, one important thing is that there are an awful lot in the lining of the arteries, what we call the endothelium.
That's a lining of the arteries, incredibly important for the arteries being able to dilate and contract, and also important because when the lining gets torn or injured, cholesterol then leaks into the wall of the artery and that begins the plaque formation, ah, of heart disease.
And nicotine has profound impacts on that.
So there are impacts on the way the cell functions.
If you're looking at an embryo that's developing, these receptors will trigger development in different ways and consequently their impacts on the way the body develops as a result of that.
Ah, and this particularly in the brain impairs the development of neurons.
So as we are adding neurons as the fetus is growing it's brain, it's going to end up with fewer neurons in the brain because of nicotine exposure during pregnancy.
Now, how do we know all this? Well, there are lots of different ways that we know this.
First of all, there's studies of animals that we can, we particularly use a lot of rats and mice in these kinds of studies.
They're small, they grow quickly and we can study them a lot faster.
We also use primates, various kinds of monkeys and, and stuff in that.
Also we can know because we can look at systems in humans that are really vulnerable.
Systems like in pregnancy, where we have a growing, the fetus and the, that system is very very vulnerable to affects, so we can look for these sorts of things, ah, in that area.
We can also just grow the cells in a lab in a cell culture and then expose them to these products and see what impact it has on individual cells.
And there are not just multiple studies, but we're talking about thousands of studies about the impact of nicotine studied through all these different systems.
Now, the nicotine system in the brain, the nicotine receptors in the brain, have impacts on memory, how well we think, how well we focus our attention, and also on emotional responses.
Now, some people think that in adults, I'm going to say that again, in adults, nicotine might slightly enhance our memory, our ability to think and our ability to focus.
There are no good human studies that prove that that's the case.
When I was up at the state they were talking about the study in Discover Magazine, I like Discover Magazine.
I read it cover to cover every month when it comes out, and there was this highly speculative article about the im, the positive impact nicotine might have on the adult brain.
And it says right in the center of the article, there are no studies that show that this is true.
And yet, this, this journalist was making this great case for how wonderful nicotine was going to be on our brains.
Well, it ain't true.
Well, at least it's not been proven true yet.
However, when we are talking about a developing brain, again we're talking about fetuses, infants, toddlers, and we're also talking about adolescents as we hit, hit that period of time when that judgment part of our brain between 15 and 25, when we develop judgment in our frontal cortex, that presence of nicotine changes the way the brain develops, and that's not a good thing.
So there are fewer nerve cells, some of the nerve cells are damaged.
There are fewer connections between the nerve cells and there's all kind of changes in the brain chemistry.
Nicotine is a very powerful stimulant of the dopamine system.
Dopamine is our pleasure reward system.
When you get dopamine you feel good.
There are all kinds of things that give us dopamine.
Nicotine is one of them.
So, what about the fetus? Well, nicotine crosses the placenta.
There are more nicotine receptors in a developing brain because the body uses those receptors to guide the development, but when you add a bunch of nicotine to that and over-stimulate those receptors, you end up with some brain cells dying and some brain cells getting malformed and the number of some brain cells not forming the connections to other brain cells that they're supposed to have.
We know in human studies we haven't really been able to check this because for obvious ethical reasons, you're not going to take 1,000 women and say you get to take the nicotine and take another 1,000 women and say you don't get to take any nicotine, and see what happens to the baby.
Nobody is going to do a study like that.
But, we have seen what happens in smokeless tobacco from the nicotine.
We've done lots and lots of studies on animals to see how the brain develops in animals, and what we can see is there's a real strong correlation between the affects of nicotine and the effects we see on human studies that are using nicotine, in human subjects that are using nicotine as well.
So in other words, they're consistent with each other.
Now, let's talk about one other thing here for a second and that is, what do you do about nicotine in pregnancy and nicotine replacement? And how do you get women to quit? Well, first of all 40 women who are pregnant, 40% of women who are pregnancy find that to be a powerful motivator and they will in fact quit smoking.
An unstressingly amount of them will go back to smoking once the baby's born, which doesn't help the baby a whole lot either, but they will quit during pregnancy.
Nicotine replacement therapy has been something that medicine has used a long time to help people quit smoking, but both ACOG and the FDA say that's a last choice in pregnancy, because we just don't want to expose the fetus to nicotine.
Well, what about harm reduction.
The concept is here that perhaps if we do something that's less dangerous, there will be fewer people that are hurt by it.
So, if we move people from tobacco to pure nicotine like in an E-cigarette that that's going to be good for them.
I just want to point out that the lowest possible risk is from quitting nicotine all together.
At that point, you've reduced your risk to zero in terms of the nicotine.
So E-cigarette are counted as great because they're going to reduce the harm.
But what happens with the 40% of women who successfully quit smoking, instead switch to E-cigarettes and still get the nicotine? I would just suggest that that's not going to be helpful for their baby and this case the harm reduction isn't really going to be a harm reduction at all.
So, this is just theoretical again.
This is smokeless tobacco again, because we don't have studies on E-cigarettes yet, but several studies, and I've just given you some quotes from a couple of them, have looked at the impact and what we see is the impact on fetal exposure mirrors what we see in animals, including adverse behavioral outcome, such as attention deficit disorders, disruptive behavioral disorders and other things that we all struggle with in the school system today.
And, I'm not going to spend much time but I just do want to mention that nicotine has an impact.
The receptors alone decrease the number of lung cells along size and volume, the lungs become less elastic and impacts the lungs too.
Okay, are there any studies then on children with E-cigarettes? And the answer is no, not yet.
But we've looked at this and second-hand smoke a lot, and we know that children who are exposed to second-hand smoke at the home, in the home have more difficulty with reading and arithmatic comprehension.
Their school test scores are lower, ah, and, so we know that there are effects from, from that.
We aren't absolutely certain that's just the nicotine, but it's certainly consistent with pure nicotine research in animals.
There is also a concept called third-hand smoke and third-hand smoke is what's left after the second-hand smoke dissipates.
So you smoke a cigarette in a room, the smoker gets the primary smoke, everybody else in the room gets the second-hand smoke that's just out in the room.
When the smoking stops, what happens to the smoke? Well, it goes some place.
Some of it's absorbed onto the walls, onto the ceiling.
Cigarette smoke is composed of lots and lots of little particles.
These particles fall like rain onto the carpeting.
When you have a little rug rat rolling around and anybody who's ever had an adorable six-month-old crawling around, of course, they never put their hand in their mouth, and they never touch anything on the floor.
And you can show that these kids have nicotine levels that are equal to our, almost equal to the kids that are exposed to second-hand smoke.
So when you move into an apartment where somebody has been smoking in that, that out gassing continues for six months to a year.
Everything that was absorbed onto the walls starts coming out again when the smoking stops.
Everything that's in the carpeting gets picked up and blown again through the air when you vacuum.
And if you're down on the carpeting, ah, the five-second rule doesn't apply because it's going to be full of nicotine.
Okay, last third-hand smoke.
What we know from that that's pure nicotine in a lot of cases and that sort of gives us a good clue that those sorts of things are still happening with nicotine.
And as mentioned earlier, ah, children get into these E-cigarette cartridges and 40% of the tobacco related calls and Poison Control Centers are related to nicotine.
So, and this is really alarming.
Now we're seeing this incredible increase in E-cigarette use in adolescents.
Adolescence is a time when higher cognitive functioning begins.
Nicotine impairs that.
Development of the prefrontal cortex, which is this area, this part of the brain, which is where our judgment comes in.
Um, and the receptors are a major influence on how this executive kind of control mechanism that we all have to control our impulses, ah, begin to occur.
This animal studies again show that nicotine has a major impact on the way that these, the brain develops at this point and adolescents are going to be really a problem with this.
And if we go back and think about just how many percentage of kids are using E-cigarettes, we've got a real cause for alarm here now.
Now, adolescents are also much more likely to become addicted to any substance they use.
DeFrance, a guy in Boston who's been studying this for a long time, just shows that nicotine really is the true gateway drug people become addicted to nicotine and that leads to experimentation with other, ah, ah, drugs.
He shows that an adolescence, meaning say from 14 to 18, smoking one cigarette a week for six weeks is enough to get 50% of the kids that are addicted, are addicted to it at that.
One cigarette a week for six weeks and 50% of kids become addicted.
But the really scary thing and the really kind of interesting thing is that about 5% of kids will literally become addicted on their first cigarette.
And he, he says you can pick those kids out because they'll tell you when they had that cigarette, it was the greatest sensation they'd ever felt.
For that moment, they felt better than they'd ever felt in their life.
And those kids are the ones that are going to get hooked really on just one cigarette.
Now, the other thing is is that we've now follow, had an opportunity, cigarettes have been out long enough to follow these kids over time.
And kids who use E-cigarettes but don't smoke and have never smoked are three to five times more likely to start smoking than kids who have never used E-cigarettes.
So they clearly are an initiator for the use of cigarettes as a whole.
So, well, doesn't that mean that this is addictive? I couldn't believe it.
They actually tried to make the claim, the state, the Legislature, that nicotine was not addictive.
God, I so wanted one of the, the Representatives to ask me a question about that, Senators, I guess it was, ask me a question about that.
I was just absolutely flabbergasted that anybody would make that claim.
But, let's go back and look at it.
I had the opportunity once to share the stage with Victor DeNoble.
He was one of the guys that used to work for the tobacco industry.
They hired him in the 1970's to produce a heart-safe cigarette.
Um, he says he was successful at it, but since Phillip Morris never really brought the cigarette out, we don't know if he was successful or not.
But, be that as it may.
He started studying.
He had to get the rats addicted to nicotine and he was using pure nicotine I.
and was just a steady drip.
He was having a little trouble with rats would kind of like it but they didn't seem to be very crazy about it.
And he was sitting in the cafeteria watching people smoke one day and he realized that people smoke intermittently.
They take a puff, they put the cigarette down.
They take a puff, put the cigarette down.
So he went back to the lab and changed his pump for the rats, so that it pulsed the nicotine and those rats went crazy for nicotine.
That pulsing creates a surge of dopamine, a drop off, a surge of dopamine and a drop off, and that leads to powerful addiction.
There are now dozens and dozens, if not hundreds of studies showing that nicotine is in fact addictive.
So, that, we ought to be able to put that aside.
Are there other substances in tobacco that also produce physical dependence? Certainly.
But it's nicotine that the tobacco industry manipulates.
One of those things that was in cigarettes is formaldehyde.
Formaldehyde is also found in tobacco.
Formaldehyde's that really great smelling stuff that they used to put the, the frogs and the rats in in your biology class to preserve it.
You have to wear gloves when you use it because it's a carcinogen.
It also is mildly addictive.
That is, you actually get physically dependent on it.
I can't imagine something that would be worse than that.
However, it's real value to the tobacco industry is that formaldehyde increases the addictiveness of nicotine.
So the more formaldehyde there is in a cigarette, the same amount of nicotine is more likely to make you addicted.
So, ammonium does the same thing and there's a fair amount of ammonium in cigarettes.
I haven't seen any reports about ammonium in E-cigarettes.
So the tobacco industry deliberately manipulates the content of other chemicals in the cigarettes to potentiate the nicotine and make it more addictive.
They wouldn't be doing that if nicotine weren't addictive in the first place.
They'd be manipulating whatever it is that really is addictive.
They're manipulating the nicotine.
Okay, so what about addiction.
Well, if you dabble with alcohol, about one out of every 10 people is going to become an alcoholic.
But hey, if you dabble with cocaine, about one out of every six people is going to get addicted to cocaine.
Okay, now take a second and just think about what the addictive potential is of nicotine.
And the answer is, that one out of every two is going to get hooked in the long run.
As I said half of them will be hooked in adolescences, one cigarette a week for six weeks, but you keep going and at least 50% of people are going to get hooked.
This isn't scientifically proven, I should say.
This is the opinion of the addiction experts at John Hopkins.
So I would take that as a reasonable effect.
Okay, what about quitting? Well, nicotine replacement, you may have already heard about that's the gum, the patch.
They make an inhaler now, a nasal squirter.
Different ways of replacing nicotine.
They work about 5% of the time.
The inhaler works a little bit better than that.
But the gum and the patch will help about 5% of people who quit smoking.
Some antidepressants have been tried and they'll help about 10% of people who quit smoking.
Chantix, which is the, another smoking aid will help about 20 % of people who quit smoking.
Counseling is in the 15-20% range and counseling and medication get up to 30%, sometimes 35%, in that range.
Ah, to put that in perspective, when a doctor tells a patient to quit, about 2% of people will quit.
So, I always used to say I'll take my 2%, but I'm not very effective at getting people to quit smoking, just by telling people to quit smoking.
I have to do something else.
So, what about E-cigarettes? Well, first of all let's point out that E-cigarettes are not FDA approved as a quit aid.
Let's also point out that no company has applied to the FDA to present data to say that they're a quit aid.
So making a claim that they're a quit aid is completely bogus from a scientific point of view or a regulatory point of view.
Now, you, it is important that you do long-term followup when you do these kinds of studies.
Your quit rate in 30 days is always going to be better than your quit rate at a year, always.
Um, survey with some other, early studies did that suggest that E-cigarettes could be a reasonable help in quitting, helping people quit smoking.
The trouble was there were methodological problems.
They didn't follow them long enough.
They didn't check to see that they were really quitting exactly.
They didn't double-check them.
Some of the questions that, were whether or not they still smoking.
So they didn't really get rid of the dual use group.
So, they kept working at the studies and the studies kept getting better and they eliminated the methodological problems and as they did, they began to see that there really was no impact.
That is, people using E-cigarettes did not quit at a greater rate.
And recently they did what is called a Meta-Analysis, which is one way of combining a whole bunch of different studies into a much larger number, so you get bigger numbers and you get better statistical probabilities because you've got more people.
And when they do that, they showed that E-cigarette users were actually 28% less likely to quit smoking than people who used other quit aids.
So, another thing is, is that 80% of E-cigarette users in several surveys, but somewhere between 60 and 80% also use traditional cigarettes.
That is, that they're dual users.
So they're really not getting the benefit of cigarette cessation anyway.
So, ah, first of all we can build a little bit.
We've been researching cigarettes for more than 40 years.
And we have learned a lot about how cigarettes cause disease, whether it's cancer, whether it's heart disease.
As I mentioned, some of the effects of the brain, but we're still really, research into pure E-cigarettes.
Still, there are some effects that have been shown.
So for example, at heart disease, one of the things you need to be able to do is to make the arteries open up, so when you're heart's stressed, your coronary arteries have to get larger so you can pump more blood to your heart too, and the heart can work harder.
You can't do that effectively if you've had nicotine in your system, because nicotine, wants the ability of an artery to open up.
It can't open it up.
It just stays stuck.
Now, you get under some stress and you can't get enough oxygen or blood going to the heart muscle, and that can cause a heart attack.
This is due to the adverse impact on the endothelium, and we know that nicotine actually kills endothelial cells.
When you give somebody nicotine and then filter their blood, you can find dead endothelial cells floating around their blood stream.
When the endothelium is damaged like that, it tears more easily just from the normal movement and then you start getting stuff from the blood stream into the artery wall, and that's how plaque forms.
Also, there are these things called platelets.
Platelets are little tiny cell particles and their function in the blood is to clump together, so when you get a cut, they clump and plug the end of the blood vessels like a cork in a bottle and stops the bleeding.
Which is why we tell people to take aspirin when they have a heart attack because aspirin tells the platelets don't clump, and we know people can get a heart attack because the blood literally clumps inside of the blood vessel, instead of when it's bleeding like it's supposed to, and that cork in a bottle can cause a heart attack because it stops the blood flowing through that artery into the heart.
We tell people to take an aspirin because it keeps the platelets from clumping together like that.
However, nicotine in the particles, particularly the particles which are in E-cigarettes, that's why you see the cloud of smoke.
Those particles tell the platelets to clump together faster so they make it worse.
Now, we actually do have one study that just came out in March of this year that showed people who used E-cigarettes had an increased risk of having a heart attack of 42% compared to people who didn't use the E-cigarettes.
So we now have one study.
That by the way is very consistent with the studies on second-hand smoke, which is about in the same ballpark.
So, harm reduction.
Well, my analogy is this.
You have a ten-story building, you jump off the building you really don't expect to survive.
I apologize, this has only nine stories if you count the roof.
I didn't have a ten-story building.
So my idea, my thought is, is, sure when you do E-cigarettes, you might be jumping out of the third floor instead of the tenth floor.
You're still likely to get hurt and you might survive.
That's harm reduction.
That's what they mean by harm reduction.
The best thing to do is to walk out on the ground floor because it's the safest way to get out of the building, not jumping.
Now, if the data on heart disease pans out the way I've outlined it, after all we only have a few studies and we're still working on this a lot, we only have to move that from the third to the fourth or fifth floor.
Okay, on my last slide and then I'll shut up, is that again, and this is a slide that Kris showed you earlier about this dramatic decrease in ah, of Montana of people using cigarettes.
But remember, I don't have, do I have a pointer on this thing? Oh yes, okay.
The, there's 30%, somewhere around here, is where the E-cigarette use is.
Now, stop and think about this.
Those kids are three to five times more likely to start smoking.
I don't know what's going to happen to this number, but with this dramatic increase in E-cigarette use, we may be seeing this bottom out and starting back up again.
Only the future will tell us that, but I'd be really alarmed at what we're seeing.
Sarah Shapiro: All right.
So, I'm Sara Shapiro, I work for Lewis and Clark Public Health and I'll be talking about the tobacco marketing, um, in Montana, specifically the point-of-sale marketing.
So each year 9.
6 billion dollars is spent on marketing tobacco.
That's 26 million dollars every day and that's over 1 million dollars an hour.
In Montana that's 30.
5 million dollars spent a year from big tobacco and 95% of that money is spent at the point-of-sale location.
So when I'm talking about point of sale, I'm talking about where we buy our milk.
Where we buy our soda.
Where we buy candy.
It's where tobacco is sold.
So that is at convenience stores, gas stations, pharmacies, etc.
So this also mainly what I'm talking about.
This is what you see when you're checking out of those places.
So you're being marketed to at all aspects of these locations, so this is the outside, the advertisements, the price discounts.
Inside you go look where the Slushies are, there's something about Marlboro.
By the ice cream you'll see it, and then you also see it near the drinks.
You see it on all angles.
No matter where you go you're going to see these advertisements.
Some price discounts right above where you're checking out.
And so I'm mainly going to talk about this power wall.
So this is where the majority of the tobacco products are located.
So when you go to check out you really can't miss it.
Raise your hand if you recognize this.
So big tobacco is targeting for specific groups.
They're targeting people who are using.
They want them to continue using the product.
People who quit, they want them to start using again.
Would be users, those are the social smokers, the every once in awhile, the when they're drinking smokers, and then youth, who is what I'll be talking about most of my presentation.
Nine out of ten tobacco users start before the age of 18 and once they start, most are hooked for a long time, or the rest of their life, and so they're trying to get these replacement smokers.
So I'll go over the tactics that are specific to big tobacco is specifically using to hook these populations.
The first is eye level is buy level so most of the tobacco products are in front of the counter are at about three feet, so that's definitely not my eye level.
It's a younger population's eye level and it's mixed in with the candy.
So they already know that kids are looking at the candy, looking at the bright colors and the flavors and ah, that is where they're putting these tobacco products, and so I'm talking a lot about cigarillos, the flavor chew, E-cigarettes as well.
So as you can see, it's at this young girl's eye level, mixed in with this gum.
So, the, the kid is at 45 inches and the poster is at 45 inches, the tobacco poster.
Another thing is flavors.
So E-cigarettes, cigarillos, they come in a million flavors.
There's bubble gum, fruit loops, strawberry, mango, root beer float.
So these are definitely flavors that are targeting the inner crowd that is looking for that candy already, and sometimes these are mixed in so they look like candy.
If you've seen the commercials recently, you can look them up and they look identical, and they also look identical because of the packaging.
A lot of these products have the really bright colored packaging, so it looks like candy.
Another tactic is price discounts, so younger populations tend to not have as much spare money.
So using discounts, coupons, buy one, get one free, um, helps it seem more affordable and seem like something they could try to hook people.
I'll read this quote.
It's "The industries extensive use of price-reducing promotions has led to higher rates of tobacco use among young people than would have occurred in the absence of these promotions.
" The U.
Surgeon General, 2012.
And so that's saying that these are working, that more people are using because of these price discounts.
So why are they going after youth? Is cause they want their replacement smokers.
So Phillip Morris, one of the main tobacco companies, has been noted saying "The ability to attract new smokers and develop them into a young adult franchise is key to brand development.
" So, they're older population is getting older, getting sick and they need to replace, they need to replace people who are going to use it for the rest of their lives.
So that is why they're going for youth.
Place is really important.
Can we raise our hands if you've been inside a gas station or convenience store in the last week.
So normally when I go to the gas station, I don't go inside any more.
I pay at the pump and I leave and I don't really go inside very often, but 70% of youth go into gas stations and convenience stores weekly.
So they're extremely vulnerable to this number, um, because of all the different advertisements.
They go during lunch to get candy.
They go on their walk home.
Um, it's kind of like a right of passage to be able to go to one of these places with your friends.
And so place is really important because of the amount of them in Helena alone and then Broadwater.
This is just our area and how many places you can see it and be victim to this advertising.
So adver, this pays off.
There's a reason that 30.
5 million dollars a year is spending in Montana.
So each day 3,300 youth under the age of 18 will try their first cigarette, 700 of these children will become regular smokers.
So it's a scary number.
Um, but it's showing that this advertising is working.
And again this is another graph showing that same thing.
It's showing how the green bars are showing the dollars spent on E-cigarette advertising and the line is showing the past 30 day great use among youth, and as you can see, as advertising goes up, so is the use among youth.
So this is just another graph showing that um, the amount of E-cigarette users is going up every year.
So this tobacco marketing is working and why we should be scared of it is because it normalizes the presence of tobacco products, meaning when youth go into these locations and they see how much tobacco is and where it is all over the place, it seems like more people are using it.
And when more people use it, the way to fit in.
So, it normalizes the idea of it.
It encourages youth to use tobacco and eventually get hooked.
It makes it harder for current users to quit.
You know they want to buy the milk, but they're seeing this tobacco product every time they try to check out.
It encourages people who quit tobacco to start using again.
So these are some pictures that I did from a recent scavenger hunt that I've been doing with the youth.
What I do is I take youth to these different locations and they have check marks and they have to check if they see products below three feet, what flavors they're seeing, what discounts are seen.
Can you see it from the road.
Things like that.
And so I'm able to work with youth to understand this and it tends to be empowering because they don't like being targeted.
You know, they want that independence and that freedom, and so they don't like how these companies are targeting them.
Um, I'm also doing presentations to multiple groups trying to get the word out because once you learn these tactics it's really hard to not notice them.
So that's one thing I encourage everyone here to do, is to go into these stores and notice them and realize them, and then tell your friends.
Tell your peers.
Tell the youth, um, to keep educating.
Nicole Aune: So, I'm just going to do a final wrap up here and kind of leave us with, so now what.
We've heard all these things.
What do we do next? What are our actions steps? So, just to talk a little bit about the, the laws that are in place now.
In January of 2016 Montana set a law that you have to be 18 in order to purchase E-cigarettes.
Before that anybody, any age, could go and get these.
You could be 7 years old and walk into a store and be able to buy an E-cigarette, which is just absolutely atrocious.
So at least now we do have that law in place.
That was set here in the state in January of 2016 and then the FDA came and set it, set a law in May of 2016 at the national level.
So now that's a national law that you have to be 18 in order to purchase these products.
Um, they are also not allowed to be sold in vending machines where kids can, where kids are present.
Um, they're not allowed to give out free samples.
And starting in May of 2018, um, if we get there with this administration, um, warning labels ah are, are going to be required.
And I thought that this, this is kind of interesting this warning label right here, because um, it, you'll hear as Dr.
Shepard said many times, you hear the E-cigarette industry saying, oh nicotine is, is actually good for you.
It's not harmful at all.
So, now you're being required to put a warning label on that explicitly states that nicotine is harmful and extremely addictive.
So, just putting that out there.
So then, we actually have some other laws here in, in Montana.
So we've had a few counties that have taken it upon themselves to include E-cigarettes in their local Clean Indoor Air Act protocols and actually Lewis and Clark County was the first county to do that.
So, yeah, Lewis and Clark County.
Round of applause.
And there are actually four other counties now from Montana that have E-cigarettes in their Clean Indoor Air Act protocol.
That's Sanders County, Carbon, Powell, and Granite recently added there then too.
I'll just mention too that in addition to those businesses in other, in other counties where this isn't a law, businesses have the authority and, and the um, and the right to ban E-cigarettes in their business.
So different businesses or housing authorities, um, hospitals, they can, they can choose to ban the use of E-cigarettes on their property.
So I did want to mention that lots of other localities across the national have taken it upon themselves to enact some policies that are even, even more strict on these products, and help protect our youth.
So in California, and Hawaii, they have made it illegal to purchase any tobacco product, including E-cigarettes, um, if you (cough) (excuse me) if you are under the age of 21.
So there are at least 225 other localities where it's illegal to purchase tobacco if you're under the age of 21.
So this is really good for a number of reasons.
Um, one is because it reduces, or it delays the age of initiation and then two, it helps keep tobacco out of schools, um, as Kris had mentioned earlier.
You have, have 18 year olds who can buy these products and they're still in high school.
When you raise the age to 21, you don't have a lot of 21 year olds who are still in high school, so it makes it difficult for those kids to be buying a tobacco product or E-cigarettes and passing along to their friends in high school.
And then the other reason is, um, it reduces sales to minors because it's harder to pass off as a 21 year old than it is to pass off as an 18 year old.
So, so doing that, that's a really, that's a really good policy that the Surgeon General promotes.
In Minnesota, they've applied a tax to E-cigarettes.
You heard Dr.
Shepard talk about how we've, we recently tried to do that and it didn't go so well.
But raising the price, raising the price on tobacco products is one of the most effective mechanisms to re, to prevent youth initiation of tobacco products.
So, like some other, um, some of our counties in Montana, New Jersey and our neighbor North Dakota, the whole state has prohibited the use of E-cigarettes in indoor public places.
So that's something that a whole state can do, is, is include that in the state Clean Indoor Air Act.
Um, Chicago has actually banned the sale of flavored products within 500 feet of a school.
So they're taking action on these flavors, because E-cigarettes, they come in 7,700 different flavors.
I mean, that, that's insane and, as Sarah mentioned, they're in all these different flavors that are appealing specifically to kids.
Um, Providence, Rhode Island has prohibited discounts like coupons and buy one, get one free.
And then New York City has actually had a law that requires that all of their tobacco products be placed behind the counter or in another area that's not freely accessible and can't just be picked up by a kid and walked out.
So this is just kind of a sample.
There are a lot of other localities across the nation that have taken action like this.
This is just a sample of some of the, some of the policies that are in place across the nation.
So what can you do? What we're wanting from the community outright is to, to know the facts so you've taken the right step today coming and hearing, hearing what we do know about E-cigarettes, so I applaud you for doing that.
The other thing is, talk to your kids and other young people about the risks associated with E-cigarettes, not just water vapor and now you guys know that.
And you know, find the right time to talk to them.
It may not just be, oh I'm going to pull my kid aside and we're going to have a sit down conversation in our living room.
Maybe take the opportunity when you're in a convenience store with your kid or with another young person, and you're seeing those tobacco products placed right next to the candy bars.
Take that moment to stop and say, "hey what do you think about this?" And get their thoughts on it.
Or if you see somebody, you're walking by somebody who's using an E-cigarette or if you're hearing, hearing advertisements on E-cigarettes.
Um, the other thing is, you know, reach out to other, other adults and, and talk to your decision makers, educate your decision makers about these products.
Like, like I said at the very beginning, there's so much misinformation about these products and depending on who you talk to, you're getting different types of, of facts.
So, it's really important that you're communicating to your decision makers and your legislatures, the real facts about these, about these E-cigarettes and what they're doing to our kids and why we're, why we're concerned.
And this can look at, look in a lot of different ways, it could, it could also take the form of, you know, writing, writing a letter to the editor for your newspaper, going and speaking at different groups.
So, so just getting, getting your voice out there is a good way too.
And the last one that I'd like to mention is, is really important, is lead by example.
You know, be tobacco-free yourself.
So if, if you are a tobacco user, there is help for you.
There's a Montana Tobacco Quit Line.
It offers free nicotine replacement therapy which is little gums and gum and lozenges and patches.
It offers reduced cost medication and free coaching.
These, these things like Dr.
Shepard mentioned, combined offer you the greatest success rate that you can get.
So there is help for you and, and it doesn't help to, it's harder for you to have a conversation with your kids about tobacco products and E-cigarettes, if you yourself are using them.
It's harder to get that message across.
So there is hope for you and your set, 1-800-QUIT-Now.